

# Physiology and pathophysiology of the calcium-sensing receptor in the kidney

Daniela Riccardi<sup>1</sup> and Edward M. Brown<sup>2</sup>

<sup>1</sup>School of Biosciences, Cardiff University, Cardiff, United Kingdom; and <sup>2</sup>Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts

Submitted 23 October 2009; accepted in final form 13 November 2009

**Riccardi D, Brown EM.** Physiology and pathophysiology of the calcium-sensing receptor in the kidney. *Am J Physiol Renal Physiol* 298: F485–F499, 2010. First published November 18, 2009; doi:10.1152/ajprenal.00608.2009.—The extracellular calcium-sensing receptor (CaSR) plays a major role in the maintenance of a physiological serum ionized calcium (Ca<sup>2+</sup>) concentration by regulating the circulating levels of parathyroid hormone. It was molecularly identified in 1993 by Brown et al. in the laboratory of Dr. Steven Hebert with an expression cloning strategy. Subsequent studies have demonstrated that the CaSR is highly expressed in the kidney, where it is capable of integrating signals deriving from the tubular fluid and/or the interstitial plasma. Additional studies elucidating inherited and acquired mutations in the CaSR gene, the existence of activating and inactivating autoantibodies, and genetic polymorphisms of the CaSR have greatly enhanced our understanding of the role of the CaSR in mineral ion metabolism. Allosteric modulators of the CaSR are the first drugs in their class to become available for clinical use and have been shown to treat successfully hyperparathyroidism secondary to advanced renal failure. In addition, preclinical and clinical studies suggest the possibility of using such compounds in various forms of hypercalcemic hyperparathyroidism, such as primary and lithium-induced hyperparathyroidism and that occurring after renal transplantation. This review addresses the role of the CaSR in kidney physiology and pathophysiology as well as current and in-the-pipeline treatments utilizing CaSR-based therapeutics.

proximal tubule; thick ascending limb; distal convoluted tubule; collecting duct; 1,25-dihydroxyvitamin D<sub>3</sub>; parathyroid hormone; hypercalcemia; hypocalcemia; hypercalciuria; calcimimetic; hyperparathyroidism; inactivating mutation; activating mutation; polymorphism; familial hypocalciuric hypercalcemia; neonatal severe primary hyperparathyroidism; autosomal dominant hypoparathyroidism

THE EXTRACELLULAR CALCIUM (Ca<sup>2+</sup>)-sensing receptor (CaSR) (21) enables key tissues participating in Ca<sup>2+</sup> homeostasis to closely monitor the blood calcium level. When it detects even minute perturbations in Ca<sup>2+</sup> from its normal level, the CaSR directly or indirectly modulates various homeostatic tissues so as to normalize Ca<sup>2+</sup>. Key CaSR-expressing, homeostatic tissues include the parathyroid hormone (PTH)-secreting parathyroid glands, calcitonin (CT)-secreting thyroidal C cells, intestines, bone, and kidney (152). The last three determine how much Ca<sup>2+</sup> moves into or out of the body (intestine and kidney, respectively) or how Ca<sup>2+</sup> moves between the extracellular fluids (ECF) and bone. These Ca<sup>2+</sup> fluxes are regulated by PTH and CT, as well as by 1,25-dihydroxyvitamin D<sub>3</sub> [1,25(OH)<sub>2</sub>D<sub>3</sub>], whose renal synthesis is homeostatically regulated. Intrarenal distribution, targets, and effectors of the CaSR are described in Table 1.

Over the past 10–15 years, there has been great progress in understanding the diverse roles of the CaSR in the kidney in health and disease, which is the focus of this article. We first

briefly review key molecular and biochemical features of the CaSR, its binding partners and signaling pathways, and the regulation of its function and expression. Because of the key roles of CaSR-regulated PTH secretion in controlling renal function, the CaSR's role in the parathyroid gland is then addressed. A more detailed description of the CaSR's functions in the kidney follows, along with a description of the impact of inherited and acquired disorders of Ca<sup>2+</sup> sensing as well as other common diseases of calcium metabolism on the CaSR and its regulation of renal function.

## Structure and Function of CaSR

The CaSR belongs to family C of the G protein-coupled receptors; family C also includes the metabotropic glutamate receptors, GABA<sub>B</sub> receptors, receptors for taste and pheromones, and an amino acid- and divalent cation-sensing receptor called GPRC6A (16, 21). Although some evidence exists that GPRC6A is a second Ca<sup>2+</sup>-sensing receptor (123), this rapidly evolving topic is beyond the scope of this discussion. The extracellular domain (ECD) of the human CaSR comprises 612 amino acids and is followed by a 250 amino acid domain of 7 transmembrane helices (TMD) and finally by a carboxy terminal (C) tail of ~200 amino acids (152). Molecular modeling based on the known structures of the ECDs of several

Address for reprint requests and other correspondence: E. M. Brown, Div. of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, EBRC, 223A, 221 Longwood Ave., Boston, MA 02115 (e-mail: embrown@partners.org); D. Riccardi, School of Biosciences, Cardiff Univ., Museum Ave., Cardiff CF10 3AX, UK (e-mail: riccardi@cf.ac.uk).

Table 1. Intrarenal distribution, targets, and effectors of the CaSR

Region	Cellular Target	Biological Effects
PCT/PST	↓ PTH1R ↑ 1-Hydroxylase activity ↑ p38 MAPK	↓ P <sub>i</sub> transport ↑ 1,25(OH) <sub>2</sub> D <sub>3</sub> synthesis ↑ VDR expression
MTAL	↑ H <sup>+</sup> -K <sup>+</sup> -ATPase ↓ Calcitonin- and AVP-induced cAMP production	↑ Urine acidification ↓ NaCl/Ca <sup>2+</sup> /Mg <sup>2+</sup> transport
CTAL	↓ CLDN-16 ↓ NKCC2 ↓ ROMK ↓ PTH-induced second messenger production	↓ Ca <sup>2+</sup> /Mg <sup>2+</sup> transport ↓ NaCl/Ca <sup>2+</sup> /Mg <sup>2+</sup> transport ↓ NaCl/Ca <sup>2+</sup> /Mg <sup>2+</sup> transport port ↓ Transcellular Ca <sup>2+</sup> transport
DCT/CNT	↑ TRPV5	↑ Ca <sup>2+</sup> reabsorption
CCD/OMCD	↑ H <sup>+</sup> -ATPase	↑ Urine acidification
OMCD/IMCD	↓ AVP-dependent AQP2 apical insertion	↓ Urine concentration
JG cells	↓ AC-V, renin gene expression	↓ Renin secretion

CaSR, calcium-sensing receptor; PCT/PST, proximal convoluted/straight tubule; MTAL, medullary thick ascending limb (TAL); CTAL, cortical TAL; DCT/CNT, distal convoluted tubule/connecting segment; CCD, cortical collecting duct; OMCD/IMCD, outer/inner medullary collecting duct; JG, juxtaglomerular; PTH, parathyroid hormone; MAPK, mitogen-activated protein kinase; NKCC2, Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> cotransporter 2; ROMK, renal outer medullary potassium K<sup>+</sup> channel; TRPV5, transient receptor potential vanilloid 5; AQP2, aquaporin 2; AC-V, type V adenylate cyclase; 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1,25-dihydroxyvitamin D<sub>3</sub>.

metabotropic glutamate receptors (mGluRs) (88) strongly suggests that the CaSR's ECD exhibits a venus flytrap (VFT)-like motif—a bilobed structure with a crevice between the two lobes thought to contain a key binding site for Ca<sub>o</sub><sup>2+</sup> (71, 144). The VFT is presumed to be open in the absence of agonist and to close upon binding Ca<sup>2+</sup>, thereby initiating conformational changes in the TMD and intracellular domains that initiate signal transduction.

During its biosynthesis, the CaSR is targeted to the endoplasmic reticulum by a signal peptide, where it dimerizes through intermolecular disulfide bonds involving cysteines 129 and 131 within each monomer (43, 124). The receptor is then extensively glycosylated in the Golgi apparatus before reaching the cell surface. The biologically active cell surface CaSR, upon binding Ca<sub>o</sub><sup>2+</sup>, activates the G proteins G<sub>q/11</sub>, G<sub>i</sub>, and G<sub>12/13</sub>, which stimulate phospholipase C (PLC) [thereby producing diacylglycerol and inositol 1,4,5-trisphosphate (IP<sub>3</sub>) (the latter of which releases Ca<sup>2+</sup> from intracellular stores)], inhibit adenylate cyclase, and activate Rho kinase, respectively (72). In addition to inhibiting adenylate cyclase via G<sub>i</sub>, the CaSR can also lower cAMP indirectly by increasing intracellular Ca<sup>2+</sup> (Ca<sub>i</sub><sup>2+</sup>), thereby reducing the activity of Ca<sup>2+</sup>-inhibitable adenylate cyclase or activating phosphodiesterase (52). In occasional cells, the CaSR activates G<sub>s</sub>, the stimulatory G protein stimulating adenylate cyclase (99). The receptor regulates diverse other intracellular signaling systems, including mitogen-activated protein kinases (MAPKs) [e.g., extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAPK, and c-Jun NH<sub>2</sub>-terminal kinase (JNK)], phospholipases A<sub>2</sub> and D, and the epidermal growth factor (EGF) receptor, a recently reviewed topic (72).

The CaSR undergoes little desensitization upon repeated exposure to agonist, at least in parathyroid cells. Its resistance to desensitization results, in part, from its binding to the large actin-binding scaffold protein filamin A and is presumably important to ensure the CaSR's persistent presence on the cell surface, thereby enabling it to continuously monitor Ca<sub>o</sub><sup>2+</sup> (72). This interaction likely tethers the receptor to the actin-based cytoskeleton, in so doing rendering it less susceptible to agonist-induced internalization. Filamin A binds several MAPK components, and the binding of the CaSR to filamin A facilitates CaSR-mediated activation of ERK1/2 (6). In addition to the G

proteins noted above and filamin A, caveolin-1 is another direct or indirect (e.g., by binding directly to filamin A and thence to the CaSR) binding partner of the CaSR (81). Caveolin-1 is a key component of caveolae, small flask-shaped invaginations of the cell surface that participate in a variety of cellular functions, prominent among which is serving as a cellular signaling center containing various signal transduction molecules (167). Other binding partners of the CaSR include the K<sup>+</sup> channels Kir4.1 and Kir4.2, the receptor activity-modifying proteins (RAMP) RAMP-1 and RAMP-3, which facilitate the translocation of the nascent CaSR to the cell surface in some cells, and the E3 ubiquitin ligase dorfins, which could participate in regulating the proteasomal degradation of the CaSR (72).

Several factors upregulate expression of the CaSR gene, including Ca<sub>o</sub><sup>2+</sup> (acting via the CaSR) (171) and calcimimetics (drugs activating the receptor by an allosteric mechanism—see below), vitamin D [through vitamin D response elements (VDRE) in the two promoters of the CaSR gene] (22), and the cytokines interleukin-1β (113) and interleukin-6 (23). Since the CaSR upregulates the VDR gene (97), there is the possibility of a synergistic interaction between VDR and the CaSR, whereby activation of the CaSR increases its own expression and that of the VDR; the latter could potentiate vitamin D action, thereby further increasing CaSR expression and action, and so forth.

#### Activators of CaSR other than Ca<sub>o</sub><sup>2+</sup>

Ca<sub>o</sub><sup>2+</sup> is not the only CaSR agonist. A variety of divalent (e.g., Mg<sup>2+</sup> and Sr<sup>2+</sup>) and trivalent (La<sup>3+</sup> and Gd<sup>3+</sup>) cations activate the receptor, as do highly positively charged organic molecules, such as the polyamines (i.e., spermine), aminoglycoside antibiotics (e.g., neomycin), protamine, and polyarginine (21, 152). These polycationic agonists are termed type 1 agonists, and they activate the receptor even without extracellular Ca<sub>o</sub><sup>2+</sup> being present. Type 2 agonists, in contrast, require the presence of some level of Ca<sub>o</sub><sup>2+</sup>, viz., in the millimolar range, to activate the CaSR (112). Type 2 agonists include various L-amino acids, especially aromatics, and allosteric activators of the receptor, the so-called calcimimetics (33, 112). One such calcimimetic, cinacalcet or Sensipar, is in wide

clinical use for suppressing severe secondary hyperparathyroidism in patients receiving hemodialysis treatment for chronic kidney disease (CKD), as described in more detail below. The physiological significance of the CaSR's activation by amino acids is uncertain, but it occurs at physiologically relevant levels of the latter and may coordinate protein/amino acid and calcium metabolism (33). Calcimimetics bind to the CaSR's TMD, while amino acids bind to the ECD, likely close to one of the key binding sites for  $\text{Ca}_o^{2+}$  (71). Calcilytics, allosteric inhibitors of the CaSR, have also been developed (56); they bind at a site in the TMD that is thought to overlap with that for calcimimetics. While calcimimetics may stabilize the CaSR's active conformation, calcilytics likely do just the opposite, stabilizing its inactive conformation.

### *Role of CaSR in Parathyroid Glands*

The CaSR controls three important aspects of parathyroid function relevant to the kidney: 1) PTH secretion, 2) PTH synthesis, and 3) parathyroid cellular proliferation (19). Individuals homozygous for inactivating CaSR mutations (126) and mice homozygous for targeted inactivation of the CaSR gene (68) have markedly elevated PTH levels and parathyroid hyperplasia despite their marked hypercalcemia. Therefore, the CaSR tonically inhibits both PTH secretion and parathyroid cellular proliferation. The CaSR also controls expression of the PTH gene by a posttranscriptional mechanism (92). The receptor may also indirectly inhibit parathyroid function by upregulating the VDR, as noted above, thereby potentiating the inhibitory actions of  $1,25(\text{OH})_2\text{D}_3$  on parathyroid cellular proliferation and PTH gene expression (50).

### *CaSR and the Kidney*

After the identification of the CaSR in bovine parathyroid in 1993, Hebert and Brown hypothesized the existence of a similar mechanism within the kidney. The idea stemmed from earlier work carried out in the late eighties by Takaichi and Kurokawa (see Refs. 20, 151). These authors demonstrated that, in isolated nephron segments, high ambient  $\text{Ca}^{2+}$  inhibits second messenger production evoked by the peptide hormones vasopressin, glucagon, PTH, and calcitonin in segments from the thick ascending limb (TAL) of Henle's loop. Because such an inhibition was pertussis toxin sensitive and was not dependent on extracellular  $\text{Ca}^{2+}$  influx, the authors hypothesized the existence of a  $\text{G}_i$ -linked "calcium receptor" similar to that proposed by Nemeth and Scarpa (110) in 1987 at the surface of bovine parathyroid cells. In addition, Brown and coworkers (40) had previously shown that, in normal human subjects in whom PTH is clamped, acute changes in serum  $\text{Ca}^{2+}$  concentrations affect  $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$ , and  $\text{Na}^+$  excretion. On the basis of these observations, Brown, Hebert, and coworkers hypothesized the existence of a renal CaSR. By the time the molecular cloning of the bovine parathyroid receptor became public knowledge (1993), further work by this group had already identified a cDNA encoding a rat kidney CaSR with homology cloning (137).

Studies carried out in the Hebert laboratory using in situ hybridization, RT-PCR of isolated nephron segments, and Northern blot analysis revealed, surprisingly, that receptor mRNA was present not only in the TAL but throughout the

kidney and, specifically, in regions not known to play a role in  $\text{Ca}^{2+}$  metabolism (136). Thus the hypothesis of a role for the CaSR beyond the  $\text{Ca}_o^{2+}$  homeostatic system began to emerge and opened an entirely new field of research in CaSR biology. Subsequently, immunohistochemical studies using anti-CaSR polyclonal antibodies confirmed the widespread distribution of the CaSR along the nephron (135) and demonstrated another unique feature of this receptor: CaSR cellular polarization appeared to be segment specific (135). Indeed, the CaSR protein is luminal in the proximal tubule and collecting duct and basolateral in the TAL of Henle's loop (Fig. 1). While to date it is unclear how this region-specific cellular targeting is achieved, this unique distribution pattern suggested that the receptor is capable of detecting changes occurring both within the urinary space and in the interstitial plasma. Such a feature allows for an integration of multiple signals, permitting fast-acting and local "fine-tuning" of physiological processes without the necessity to evoke systemic changes in plasma composition. Studies performed over the past decade have clearly demonstrated that the CaSR plays an essential role in divalent cation homeostasis by modulating the actions of PTH in the kidney. However, more recent observations show that activation of the CaSR can directly affect many aspects of renal function. From studies using CaSR-knockout mice, isolated nephron segments, and kidney-derived cell lines, it is now apparent that CaSR plays a role in the renal control of 1)  $\text{Ca}/\text{inorganic phosphate (P}_i\text{)}$  homeostasis (7); 2) mono- and divalent cation transport (65); 3) urinary acidification (133); 4) urine concentration (133, 142); and 5) renin release (11, 96). While the indirect roles of the CaSR in regulating renal function have been extensively covered elsewhere (152), this review emphasizes direct effects of CaSR activation on renal function.

*CaSR in proximal tubule.* The CaSR is present in the subapical region of proximal tubular cells (135), where it is involved in the regulation of PTH-mediated  $\text{P}_i$  excretion (7). Studies carried out in proximal tubule-derived cell lines also suggest that  $1\alpha$ -hydroxylase activity is inhibited in the presence of high  $\text{Ca}^{2+}$  (97). Recent studies carried out with a murine model in which the full-length CaSR has been ablated (and that expresses an exon 5-less splice variant, therefore representing a "hypomorph" in some tissues) have shown that CaSR dampens the response to  $1,25(\text{OH})_2\text{D}_3$  independently of PTH actions (39). Thus CaSR exerts a tight control on circulating  $1,25(\text{OH})_2\text{D}_3$  both at the level of its synthesis (in the proximal tubule) and in modulating its effects (specifically, on calcium reabsorption by the distal tubule, see below). Conversely,  $1,25(\text{OH})_2\text{D}_3$  (22), PTH, and dietary phosphate modulate both CaSR gene and protein expression in the proximal tubule (138), suggesting the existence of a local feedback loop for the regulation of  $\text{Ca}_o^{2+}$  and  $\text{P}_i$  excretion independently of systemic changes in calciotropic hormones.

*CaSR in TAL of Henle's loop.* About 20–25% of the filtered calcium is reabsorbed in the loop of Henle, largely by the cortical (CTAL) and, to a lesser extent, by the medullary (MTAL) thick ascending limb, through both transcellular and paracellular routes (65). The CaSR is expressed at the basolateral side of TAL cells, where it directly controls both paracellular and transcellular  $\text{NaCl}$  and divalent cation transport. Basolateral, but not urinary, increases in plasma  $\text{Ca}^{2+}$  (or  $\text{Mg}^{2+}$ ) concentrations diminish their own reabsorption (128). Indeed, in the TAL, the bulk of the divalent cation reabsorption




Fig. 1. Intrarenal localization and roles of the calcium-sensing receptor (CaSR). Cellular polarity of the CaSR is apical [in the proximal tubule and outer/inner medullary collecting duct (OMCD/IMCD)] and basolateral [in the thick ascending limb (TAL) and, occasionally, in the cortical collecting duct (CCD)]. Species differences exist in the distal convoluted tubule (DCT)/connecting segment (CNT), where receptor expression can be detected apically and/or basolaterally/intracellularly. PCT/PST, proximal convoluted/straight tubule; tDL/tAL, thin descending/ascending limb; MTAL/CTAL, medullary/cortical thick ascending limb; JGA: juxtaglomerular apparatus; TRPV5, transient receptor potential vanilloid 5; PMCA, plasma membrane  $\text{Ca}^{2+}$ -ATPase; VitD, vitamin D; VDR, vitamin D receptor; NKCC2,  $\text{Na}^+$ - $\text{K}^+$ - $2\text{Cl}^-$  cotransporter 2; ROMK, renal outer medullary potassium  $\text{K}^+$  channel; PTH, parathyroid hormone; AQP2, aquaporin 2.

proceeds through the paracellular pathway and is proportional to the transtubular electrochemical driving force (35). This, in turn, is heavily reliant on the rate and extent of  $\text{Na}^+$  reabsorption. Seminal work done in the Hebert laboratory (64, 65) has been instrumental in understanding the key molecular players involved in  $\text{Na}^+$ ,  $\text{Cl}^-$ , and  $\text{K}^+$  transport by the TAL and the modulatory role played by the CaSR in this nephron segment. The apical  $\text{Na}^+$ - $\text{K}^+$ - $2\text{Cl}^-$  cotransporter NKCC2 (*SLC12A2*) and the renal outer medullary potassium  $\text{K}^+$  (ROMK) channel (*Kir1.1*, *Kcnj1*) generate the “driving force” for paracellular cation transport (64). While  $\text{NaCl}$  reabsorption through NKCC2 is electroneutral (NKCC2 translocates 1  $\text{Na}^+$ , 1  $\text{K}^+$ , and 2  $\text{Cl}^-$  ions from the lumen into the cell), apical  $\text{K}^+$  represents the rate-limiting step of this process and  $\text{K}^+$  ions back-diffuse into the lumen through the ROMK channels (65).  $\text{Na}^+$  and  $\text{Cl}^-$  accumulated inside the cell are then transported into the bloodstream through basolateral  $\text{Na}^+$ - $\text{K}^+$ -ATPase and  $\text{Cl}^-$  channels, respectively. Overall, these processes yield a net cellular reabsorption of  $\text{NaCl}$  and the generation of a lumen-positive transepithelial potential difference, which drives non-selective cation reabsorption (largely  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  but also  $\text{Na}^+$ ) through the paracellular route (65).

During hypercalcemia, activation of the basolateral CaSR inhibits ROMK channels (164), which contribute to the recycling of  $\text{K}^+$  into the lumen of the TAL (14). This action of hypercalcemia limits the rate of  $\text{Na}^+$ - $\text{K}^+$ - $2\text{Cl}^-$  cotransport by reducing the availability of luminal  $\text{K}^+$ . Thus the greater the hypercalcemia, the greater is the inhibition of ROMK and NKCC2 and the faster the dissipation of the lumen-positive transepithelial voltage. The end point result is that CaSR activation abrogates paracellular  $\text{Na}^+$ ,  $\text{Ca}^{2+}$ , and  $\text{Mg}^{2+}$  transport, producing a “Bartter-like” phenotype (159). The signaling pathways underpinning the inhibitory effects of CaSR activation on NKCC2 and ROMK activities involve, at least in part, production of *P*-450 metabolites and/or of prostaglandins (66, 163, 164). In addition,  $\text{Mg}^{2+}$  is largely reabsorbed in the TAL (129), and mutations in claudin-16 (*CLDN-16*), an integral component of the tight junctional complex in this nephron segment, cause familial hypomagnesemia with hypercalciuria (146). Thus in the TAL *CLDN-16* acts as the “gatekeeper” for paracellular  $\text{Mg}^{2+}$  transport. Recent studies have demonstrated that the CaSR agonists  $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$ , neomycin, and  $\text{Gd}^{3+}$  induce lysosomal translocation of *CLN-16* in Madin-Darby canine kidney (MDCK) cells, a model for TAL/distal tubule,

thus enhancing its degradation and further contributing to a reduction in  $Mg^{2+}$  transport (73).

In the MTAL water permeability is minimal because of the absence of luminal aquaporins, and water reabsorption does not follow paracellular divalent cation movements. The reduced permeability of this nephron segment would yield a rapid increase in basolateral  $NaCl$  and/or  $Ca^{2+}/Mg^{2+}$  concentration, which could inhibit  $NKCC2$ ,  $ROMK$ , and, possibly,  $CLN-16$  (see above). However, an increase in ionic strength (as would occur in the event of increased transport of  $NaCl$  into the basolateral fluid) reduces  $CaSR$  affinity for  $Ca^{2+}$  (132), and allows for paracellular mono- and divalent cation movements to occur even in the face of a rise in basolateral  $Ca^{2+}$  concentration.

Furthermore, it is well established that the TAL is also involved in the active reabsorption of  $NH_4^+$ , both via  $NKCC2$ , where  $NH_4^+$  can replace  $K^+$  on the cotransporter (3), and, as for other cations, through the transepithelial, potential difference (PD)-driven, paracellular route (84). Since  $CaSR$  affinity for  $Ca^{2+}$  and  $Mg^{2+}$  is also affected by pH (with alkalization increasing it and acidification decreasing it) (131), in the TAL the receptor integrates signals deriving from an increase in basolateral  $Ca^{2+}$  concentration with the acid content of the medullary interstitium. While it is well established that acidification affects  $Ca^{2+}$  solubility and excretion, further work is necessary to elucidate the link between  $CaSR$  activation and urinary pH. In this nephron segment  $CaSR$  activation has also been reported to induce apical  $H^+$  secretion in mouse TAL (44). Whether modulation of  $CaSR$  function affects the reabsorption of  $NH_4^+$  and/or of  $HCO_3^-$  through inhibition of the sodium/hydrogen exchangers  $NHE1/NHE3$  (24, 54) and/or of the anion exchanger  $AE2$  (130) is currently unknown.

Finally, in the CTAL PTH evokes transcellular calcium transport (48). Studies carried out by Friedman and coworkers (49, 107) have demonstrated that  $CaSR$  activation with  $Gd^{3+}$  or neomycin inhibits PTH-stimulated apical  $Ca^{2+}$  entry, possibly through protein kinase A and C signaling. Basolateral  $Ca^{2+}$  exit is likely to occur through a  $Na^+/Ca^{2+}$  exchanger ( $NCX$ ) and the plasma membrane  $Ca^{2+}$ -ATPase ( $PMCA$ ). In purified membranes of MDCK cells expressing the  $CaSR$ , high  $Ca^{2+}$  suppresses  $PMCA$  activity (12). Together, these observations suggest that  $CaSR$  activation in the TAL controls both the apical and the basolateral components of transcellular  $Ca^{2+}$  movements. These concerted actions allow for an active, regulated reabsorption while minimizing the risks of intracellular  $Ca^{2+}$  overload.

*CaSR in distal convoluted tubule.* The distal convoluted tubule (DCT) and connecting tubule (CNT) account for ~15% of total  $Ca^{2+}$  reabsorbed by the kidney, and calcium reabsorption in these nephron segments is inversely related to  $Na^+$  transport. In DCT and CNT, the transepithelial PD is against  $Ca^{2+}$  reabsorption and the paracellular permeability of  $Ca^{2+}$  ions is very low (48).  $Ca^{2+}$  reabsorption is an active, transcellular process, which is regulated by PTH and  $1,25(OH)_2D_3$  (48, 69). Thus  $Ca^{2+}$  ions enter the apical membrane through the epithelial  $Ca^{2+}$  channel transient receptor potential vanilloid member 5 (TRPV5) and are shuttled toward the basolateral membrane by calbindin D28K (69).  $Ca^{2+}$  then leaves the cell via extrusion through the  $Na^+/Ca^{2+}$  exchanger  $NCX1$  and the plasma membrane  $Ca^{2+}$ -ATPase  $PMCA1b$  (69). The  $CaSR$  is present on the basolateral cell surface and intracellularly in rat

DCT (135); it is also expressed apically, in a punctuate pattern, in the human DCT (155). Using immunohistochemistry on frozen sections from human kidney tissue, Topala et al. (155) reported colocalization of  $CaSR$  with TRPV5 at the apical membrane and in subapical vesicles of DCT and CNT cells. In cell lines overexpressing TRPV5 (or TRPV6) and  $CaSR$ , receptor activation increased the activity of TRPV5, but not that of its close homolog TRPV6. Since  $Ca^{2+}$  and  $Na^+$  reabsorption are largely coupled in the TAL (see above), increasing  $Na^+$  wasting in the urine would enhance  $Ca^{2+}$  delivery to the DCT/CNT. The attendant increase in urinary  $Ca^{2+}$  would activate TRPV5 through stimulation of the  $CaSR$  in the DCT/CNT, resulting in an increase in luminal  $Ca^{2+}$  entry (155), and prevent excessive urinary  $Ca^{2+}$  loss in a setting of urinary  $Na^+$  wasting in the TAL. Basolateral  $Ca^{2+}$  exit appears to be mediated by  $NCX$  and  $PMCA$ . Available evidence suggests that at least one of these is controlled by the  $CaSR$  (see above). Thus it is likely that the  $CaSR$  controls apical  $Ca^{2+}$  influx (70, 155) and/or basolateral exit (70) in the DCT/CNT.

*CaSR in collecting ducts.* Some rat (135) and human (Searchfield LE, Riccardi D, unpublished observations) type A intercalated cells of the cortical collecting ducts (CCD) express  $CaSR$  immunoreactivity apically, basolaterally, and intracellularly. Since hypercalcemia (and the attendant hypercalciuria) is a known cause for urine acidification,  $CaSR$  localization suggests that receptor activation could link between signals deriving from hypercalciuria, acidification, and increased diuresis. In a recent study carried out with the hypercalciuric TRPV5-knockout mouse model, homozygous ablation of TRPV5 yielded the expected hypercalciuria but no kidney stones (133). However, the mice exhibited a marked urinary acidification and increased urine flow. Furthermore, when TRPV5<sup>-/-</sup> mice were bred with mice lacking the B1 subunit of the  $H^+$ -ATPase (hence producing a "double knockout"), they manifested severe nephrocalcinosis and died in the first 3 months of life, suggesting that acidification occurred as a compensatory mechanism to ensure adequate solubility of  $Ca^{2+}$  in the urine. Exposure of outer medullary collecting ducts dissected from TRPV5<sup>-/-</sup> mice to the  $CaSR$  agonists  $Ca^{2+}$  and neomycin promoted  $H^+$  secretion via  $H^+$ -ATPase and aquaporin 2 (AQP2) downregulation (133), leading to acidification and polyuria. These effects of  $CaSR$  activation on acidification could not be seen in the "double-knockout" TRPV5<sup>-/-</sup>/B1<sup>-/-</sup> mice. Together, these experiments indicate that activation of the  $CaSR$  induces urine acidification and a reduction in water reabsorption, thereby allowing for urinary  $Ca^{2+}$  excretion to proceed in the presence of a reduced risk of kidney stone formation.

The effects of  $CaSR$  activation on urinary concentrating ability are even more obvious in the inner medullary collecting duct (IMCD). It is well established that hypercalcemia can lead to hypercalciuria, urinary concentrating defects, and polyuria, and the IMCD is the site that controls the final production of urine (17). This nephron segment is composed almost exclusively of principal cells, which express apical  $CaSR$  (142), where the receptor monitors urinary  $Ca^{2+}$  excretion. Immunohistochemical studies have demonstrated that, in this region, the  $CaSR$  colocalizes with the vasopressin-regulated AQP2 water channels (142), but not with AQP3 or 4, which are constitutively expressed at the basolateral membrane. Moreover, exposure of isolated IMCD to  $Ca^{2+}$  concentrations comparable to those seen during hypercalciuria blunts the vaso-

pressin-mediated increase in osmotic water permeability, which is accomplished through apical insertion of endosomes containing AQP2 water channels (142). Furthermore, the authors demonstrated that apical IMCD endosomes contain AQP2, CaSR, and the signaling machinery necessary for apical insertion of this water channel. In addition, chronic hypercalcemia markedly downregulates the expression of APQ2 protein by a posttranscriptional mechanism (141). Subsequent observations made in collecting duct-derived cell lines endogenously expressing the CaSR have shown that these effects of high  $\text{Ca}^{2+}$  on AQP2 translocation could be ascribed to CaSR signaling (156). Thus hypercalcemia produces a diuretic-like effect in the TAL and also reduces urinary concentrating ability by acting on the CaSR in the IMCD (65). Disturbances of AQP2 trafficking produce nephrogenic diabetes insipidus, and patients with activating mutations in the CaSR gene can develop severe hypercalciuria with nephrolithiasis and nephrocalcinosis (121). Together, these observations suggest the possibility of using CaSR modulators to alter AQP2 targeting and/or CaSR sensing in patients with abnormal urinary concentrating ability (e.g., nephrogenic diabetes insipidus or cardiovascular disease) (108, 127) or in stone formers.

**CaSR in juxtaglomerular apparatus.** A variety of stimuli trigger renin secretion by juxtaglomerular (JG) cells of the lamina media of the afferent arteriole (9), largely through production of intracellular cAMP (11). Recent evidence suggests that the CaSR is expressed in JG cells and that activation of the receptor decreases renin secretion by suppressing the activity of the  $\text{Ca}^{2+}$ -inhibitable type V adenylate cyclase (AC-V) (115), and through stimulation of calcium/calmodulin-activated phosphodiesterases (114). Several earlier studies had shown that decreases in  $\text{Ca}_o^{2+}$  concentration produce large increases in basal and stimulated renin release (47). While significant changes in  $\text{Ca}^{2+}$  concentration in the renal cortical interstitium are unlikely under normal circumstances, other factors, such as an increase in the distal delivery of NaCl or sustained acidification, could affect renin production and/or secretion through modulation of CaSR function. This hypothesis is consistent with the phenotype of those patients affected by Bartter syndrome type V, who exhibit increased circulating levels of renin and aldosterone and normal to low blood pressure as a consequence of activating CaSR mutations (166).

#### *Role of CaSR in Other Tissues Participating in $\text{Ca}_o^{2+}$ Homeostasis*

Additional tissues that participate in  $\text{Ca}_o^{2+}$  homeostasis are the thyroidal C cells and CaSR-expressing cells of the intestines, bone, lactating breast, and placenta. The CaSR in the C cell mediates a  $\text{Ca}_o^{2+}$ -evoked, homeostatically appropriate stimulation of the hypocalcemic hormone CT (78), although CT's hypocalcemic action is much greater in some species (i.e., rodents) than in humans. A recent review by Hebert and Geibel (52) summarized the CaSR's various roles in the gastrointestinal tract. In the stomach, it stimulates gastric acid and gastrin secretion; in the small intestine, it enhances cholecystokinin release, which stimulates pancreatic enzyme secretion and gallbladder contraction. In the colon, it enhances differentiation of colonocytes (thereby reducing colonic neoplasia in some settings) (77) and inhibits fluid and electrolyte secretion, which could potentially serve as a treatment for diarrheal

disease (52). The CaSR may also mediate known actions of  $\text{Ca}_o^{2+}$  to upregulate proteins participating in duodenal intestinal  $\text{Ca}^{2+}$  absorption in vivo (157), although the CaSR's involvement and the physiological relevance of these actions are uncertain.

The CaSR's presence and roles in bone cells have been controversial (for review, see Ref. 32). However, recent evidence strongly supports the receptor's expression in osteoclast precursors and mature osteoclasts as well as in preosteoblasts and osteoblasts. While the CaSR appears to serve a permissive role in osteoclastogenesis, high  $\text{Ca}_o^{2+}$  concentrations (5–20 mM) directly inhibit osteoclast activity and stimulate their apoptosis (106). How the receptor mediates both stimulatory and inhibitory effects on cells of the osteoclast lineage is uncertain. In osteoblasts, the CaSR is mitogenic for preosteoblasts, promotes cellular differentiation, and enhances bone formation in vitro and in vivo (26, 37). Thus high  $\text{Ca}_o^{2+}$  stimulates bone formation and inhibits bone resorption in a homeostatically appropriate manner. The CaSR participates in fetal  $\text{Ca}_o^{2+}$  homeostasis by regulating placental calcium transfer (86). Recent studies have also highlighted the CaSR's previously unrecognized roles in the lactating breast, where it both stimulates transport of  $\text{Ca}^{2+}$  into the milk and inhibits secretion of the bone-resorbing,  $\text{Ca}_o^{2+}$ -elevating hormone PTH-related protein (PTHrP) when blood  $\text{Ca}^{2+}$  levels are sufficient to support elaboration of  $\text{Ca}^{2+}$ -rich milk (158).

#### *Role of CaSR in Integrating $\text{Ca}_o^{2+}$ Homeostasis*

The  $\text{Ca}_o^{2+}$  homeostatic system has three key components: 1) cells, tissues, and organs transporting  $\text{Ca}^{2+}$  into or out of the ECF [kidney, intestine and bone (and, in some stages of the life cycle, placenta and breast)]; 2) hormones regulating these fluxes [PTH, CT, PTHrP, and  $1,25(\text{OH})_2\text{D}_3$ ]; and 3)  $\text{Ca}_o^{2+}$  sensors (principally the CaSR) controlling the production/secretion of those hormones or the  $\text{Ca}^{2+}$  fluxes themselves. During hypercalcemia, for example, high  $\text{Ca}_o^{2+}$  inhibits PTH secretion and  $1,25(\text{OH})_2\text{D}_3$  synthesis and stimulates CT secretion. The increase in CT inhibits bone resorption. The increase in  $\text{Ca}_o^{2+}$  and the resultant decrease in PTH secretion, through their combined actions on osteoclasts and osteoblasts, promote net movement of  $\text{Ca}^{2+}$  into bone while also enhancing renal  $\text{Ca}^{2+}$  excretion by inhibiting distal tubular  $\text{Ca}^{2+}$  reabsorption (165). The reduction in  $1,25(\text{OH})_2\text{D}_3$  decreases  $\text{Ca}^{2+}$  reabsorption in DCT, suppresses bone resorption by inhibiting  $1,25(\text{OH})_2\text{D}_3$ -stimulated, osteoblast-mediated bone resorption, and diminishes intestinal  $\text{Ca}^{2+}$  absorption. The resultant decrease in net  $\text{Ca}^{2+}$  release from bone, combined with reductions in intestinal absorption and renal tubular reabsorption of  $\text{Ca}^{2+}$ , normalizes  $\text{Ca}_o^{2+}$ . The homeostatic response to hypocalcemia involves largely opposite changes in the processes just described.

#### *Inherited and Acquired Disorders Impacting Function of CaSR in Kidney*

Table 2 describes conditions impacting the CaSR in the kidney.

**Familial hypocalciuric hypercalcemia.** Familial hypocalciuric hypercalcemia (FHH) is a benign, autosomal dominant form of hypercalcemia with characteristic abnormalities in the regulation of parathyroid and renal function by  $\text{Ca}_o^{2+}$  (91, 102).

Table 2. Conditions impacting the CaSR in the kidney

Type of Condition	Name	Biological Effects
1. Genetic diseases with CaSR dysfunction in all CaSR-expressing tissues	a. FHH, NHPT, and NSHPT	a. ↓ Sensitivity to $\text{Ca}_o^{2+}$ with relative or absolute hypocalciuria
	b. ADH	b. ↑ Sensitivity to $\text{Ca}_o^{2+}$ with relative or absolute hypercalciuria
	c. Bartter syndrome type V with activating CaSR mutations	c. Hypokalemia, hyperreninemia, and hyperaldosteronism
2. Polymorphisms in the CaSR gene*	a. Glycine at codon 990 in CaSR C tail	a. Apparent receptor activation. Hypercalciuria, ↓ PTH levels, and ↑ PTH suppressibility in patients with renal failure and 2° HPT
3. Acquired disorders with CaSR dysfunction in multiple tissues	b. 986A, 990C, and 1011G haplotype	b. Greater risk of stones in PHPT
	a. Inactivating autoantibodies to the CaSR (AHH)	a. ↓ Sensitivity to $\text{Ca}_o^{2+}$ with relative or absolute hypocalciuria
4. Primary renal dysfunction impacting the CaSR in the kidney	b. Activating autoantibodies to the CaSR†	b. ↑ Sensitivity to $\text{Ca}_o^{2+}$ with relative or absolute hypocalciuria
	Renal insufficiency	Reduced CaSR expression‡ and hypocalciuria
5. Modulation of CaSR by endogenous ligands	Hypercalcemia	Urinary concentrating defect, hypercalciuria, and ↓ $1,25(\text{OH})_2\text{D}_3$ synthesis.

FHH, familial hypocalciuric hypercalcemia; NHPT, neonatal hyperparathyroidism; NSHPT, neonatal severe primary hyperparathyroidism; ADH, autosomal dominant hypoparathyroidism; AHH, autoimmune hypocalciuric hypercalcemia;  $\text{Ca}_o^{2+}$ , extracellular calcium; HPT, hyperparathyroidism; PHPT, primary HPT; \*For additional examples of the impact of polymorphisms on CaSR function, see text. †Impact on renal calcium handling not known. ‡Level of expression determined in rats with experimental renal insufficiency, not known in human renal disease. §Decrease in  $1,25(\text{OH})_2\text{D}_3$  probably results indirectly from CaSR inhibition of PTH secretion as well as through direct inhibition of 1-hydroxylase by CaSR in proximal tubule.

It is caused in most cases by heterozygous inactivating mutations of the CaSR gene, which resides on the long arm of chromosome 3 (3q13.3–q21) [also called hypocalciuric hypercalcemia, familial, type 1 (HHC1, 145980) in the Online Mendelian Inheritance in Man (OMIM)]. Missense mutations are most common, but nonsense, insertion, deletion, and splice site mutations also occur. Most families have their own unique mutation, and well over 100 such mutations have been described (see calcium-sensing receptor database at <http://www.casrdb.mcgill.ca/>). About 30% of FHH families do not have an identifiable mutation in the coding region of the CaSR or within RNA splice sites of the gene. Some probably harbor mutations in the CaSR gene's regulatory regions controlling its expression, although no such mutations have been discovered to date. Two families with clinical features similar to FHH showed linkage to the short (19p13.3) (HHC2, OMIM 145981) or long (19q13) arms of chromosome 19 (63, 95), respectively. FHH linked to chromosome 19q13 is called the Oklahoma variant (HHC3, OMIM 600740); this form of FHH exhibits overtly elevated PTH levels, and the biochemical abnormalities tend to worsen with time (95). Thus FHH is genetically heterogeneous.

FHH patients typically exhibit asymptomatic, mild-to-moderate, PTH-dependent hypercalcemia of ~11 mg/dl (total calcium) and an inappropriately normal or even overtly low urinary  $\text{Ca}^{2+}$  excretion despite their hypercalcemia (91, 101, 102). Serum  $\text{Mg}^{2+}$  levels are often high-normal or mildly elevated, suggesting that the CaSR contributes to “setting”  $\text{Mg}_o^{2+}$  as well as  $\text{Ca}_o^{2+}$  (150). Serum PTH is generally normal, although ~15–20% of patients have elevated levels (62). Serum phosphate is usually normal or mildly decreased, and serum  $1,25(\text{OH})_2\text{D}_3$  (89) and bone mineral density (BMD) are normal, although bone turnover markers may be mildly elevated (91). Because of its benign natural history and the prompt recurrence of hypercalcemia in patients with FHH following anything less than total parathyroidectomy, the standard of care is expectant follow-up without medical or surgical

intervention. Only in rare FHH families does unusually severe neonatal hypercalcemia (see below) (8), pancreatitis (122), or hypercalciuria and overtly elevated serum PTH levels (25) dictate parathyroidectomy.

The inappropriately normal (i.e., nonsuppressed) PTH level in FHH reflects a right shift in the set point for  $\text{Ca}_o^{2+}$ -regulated PTH release (i.e., the level of  $\text{Ca}_o^{2+}$  half-maximally inhibiting PTH release) (5, 80). This “resetting” of parathyroid function contributes importantly to the pathogenesis of hypercalcemia in FHH (19). Not surprisingly, the parathyroid glands of patients with FHH either are normal or exhibit subtle hyperplasia (90, 153). How can a normal PTH level and near normal parathyroid mass in FHH sustain hypercalcemia? The answer likely lies in the “collaboration” between the alteration in  $\text{Ca}_o^{2+}$ -regulated PTH release and the characteristically avid renal  $\text{Ca}^{2+}$  (and  $\text{Mg}^{2+}$ ) reabsorption described below. Consequently, less PTH is needed to maintain a given degree of hypercalcemia in FHH than in primary hyperparathyroidism (PHPT).

There is a substantial reduction in renal  $\text{Ca}^{2+}$  clearance in FHH, and the ratio of  $\text{Ca}^{2+}$  clearance to creatinine clearance, the most useful parameter of renal  $\text{Ca}^{2+}$  handling in this condition, is <0.01 in ~80% of patients. About 80% of patients with PHPT, in contrast, have values >0.01 and commonly >0.02 (29, 101).  $\text{Mg}^{2+}$  clearance is reduced but to a lesser degree (~30%) in FHH (101). Thus even with a degree of hypercalcemia comparable to mild to moderate PHPT and a lower PTH level than in the latter, FHH patients excrete less  $\text{Ca}^{2+}$  at any given level of serum  $\text{Ca}^{2+}$ .

Attie et al. (4), in a now-classic study, investigated renal  $\text{Ca}^{2+}$  handling in hypoparathyroid FHH patients or hypoparathyroid control subjects at various serum  $\text{Ca}^{2+}$  concentrations. Because the FHH patients and control subjects were both hypoparathyroid, there were no confounding changes in parathyroid function during the study that could impact renal  $\text{Ca}^{2+}$  handling. There was a marked rightward and downward shift in the relationship between serum and urine  $\text{Ca}^{2+}$  (e.g., the set

point for  $\text{Ca}_o^{2+}$ -regulated renal  $\text{Ca}^{2+}$  excretion) in FHH patients. Of note, there was a decrease in not only the calciuric but also the natriuretic response to  $\text{Ca}^{2+}$  infusion in the hypoparathyroid FHH patients (4). This likely reflects reduced CaSR activity in the TAL and is consistent with the “signature” of linked cation handling in this nephron segment (e.g.,  $\text{Na}^+$ ,  $\text{Ca}^{2+}$ , and  $\text{Mg}^{2+}$ ) in CTAL described previously (65). Indeed, the loop diuretic ethacrynic acid, which inhibits the NKCC in the TAL, produced an exaggerated calciuric response in the FHH patients (4), suggesting the relevance of excessively avid  $\text{Ca}^{2+}$  reabsorption in TAL to the hypocalciuria in FHH.

Renal water handling is also altered in FHH. As noted above, raising luminal  $\text{Ca}_o^{2+}$  in the IMCD substantially inhibits vasopressin-stimulated water flow (141, 142), owing to activation of the apical CaSR. In a study comparing water handling in patients with FHH to those with PHPT, the latter showed an ~20% reduction in their maximal urinary concentration during an 18- to 22-h dehydration test compared with FHH patients with a similar degree of hypercalcemia (103). This study illustrates “resistance” of the urinary concentrating mechanism, most likely in the IMCD, to hypercalcemia in FHH. A reduction in the CaSR-mediated, inhibitory action of hypercalcemia on NaCl reabsorption in MTAL in FHH patients may also contribute to their normal or near normal urinary concentrating ability despite their hypercalcemia (65).

*Neonatal severe primary hyperparathyroidism.* Neonatal severe primary hyperparathyroidism (NSHPT) (OMIM 239200) typically presents in the first 6 months of life (57, 58, 104, 134), often in the immediate neonatal period, with severe, symptomatic, PTH-dependent hypercalcemia and the bony changes of severe hyperparathyroidism. Infants with NSHPT can also manifest polyuria, dehydration, hypotonia, and failure to thrive (38, 59, 104). The bone disease can produce multiple fractures of long bones, ribs (sometimes impairing respiration), and other sites (38). Total serum  $\text{Ca}^{2+}$  levels range from moderately elevated (e.g., ~12–14 mg/dl) to as high as 25–30 mg/dl (19, 59, 85, 104). PTH levels are frequently 10-fold or more above the upper normal limit. NSHPT is most commonly caused by homozygous (58, 125, 126) or, rarely, compound heterozygous mutations in the CaSR gene (85) (in the latter, an infant inherits one inactivating CaSR mutation from one parent and a second from the other). There is relative or absolute hypocalciuria in NSHPT (30, 104), although  $\text{Ca}^{2+}$  excretion can be elevated in some cases, presumably owing to the markedly increased filtered load of  $\text{Ca}^{2+}$ .

Early diagnosis is critical, as untreated NSHPT can have a fatal outcome or severe impairment of subsequent mental, skeletal, and somatic growth without parathyroidectomy to alleviate the hyperparathyroidism and hypercalcemia (30, 61). Total parathyroidectomy produces hypoparathyroidism; thus hypercalcemia in NSHPT is PTH dependent, and loss of  $\text{Ca}^{2+}$  receptors in tissues other than the parathyroid (e.g., kidney, C cell) is insufficient to sustain hypercalcemia. A potentially useful temporizing measure in a severely ill neonate with NSHPT is the use of a bisphosphonate such as pamidronate, which can lower serum  $\text{Ca}^{2+}$  concentration substantially and allow stabilization before surgery, if the latter is indicated (46, 162). Remission of hyperparathyroidism after parathyroidectomy produces rapid clinical improvement and healing of bony lesions within weeks to months; the prognosis thereafter is usually excellent (31, 61, 67, 148).

Some neonates have a substantially milder clinical presentation (61, 120), a condition termed neonatal hyperparathyroidism (NHPT) to emphasize this milder phenotype (19, 119). Infants with NHPT can harbor heterozygous inactivating CaSR mutations. In some cases a mutation exerting a dominant-negative action may produce NHPT rather than the benign FHH phenotype otherwise expected with heterozygous inactivating CaSR mutations (120). Over time, NHPT can revert to FHH with only routine medical follow-up (60, 61). Parathyroidectomy should be reserved for severely affected NHPT infants, in whom substantial hypercalcemia and/or hyperparathyroid bone disease persist despite intensive medical treatment. Such cases, however, are the exception rather than the rule.

The marked increases in circulating PTH level despite severe hypercalcemia in NSHPT demonstrate a severe defect in  $\text{Ca}_o^{2+}$ -regulated PTH secretion, with potentially total or near total failure of suppression of secretion at high  $\text{Ca}_o^{2+}$  (67, 104). Two in vitro studies have addressed this point, utilizing parathyroid tissue from two cases of NSHPT undergoing parathyroidectomy. In the first case (100),  $\text{Ca}_o^{2+}$ -regulated-PTH secretion from dispersed parathyroid cells revealed a set point of 2.5 mM, more than twice the normal value of 1 mM. In the second case, there was minimal suppressibility of PTH secretion at 2.0 mM  $\text{Ca}_o^{2+}$  (34).

There are also limited data on the relationship between serum and urinary  $\text{Ca}^{2+}$  concentrations in NSHPT. In the cases in which it has been measured, there can be relative or absolute hypocalciuria, or sometimes hypercalciuria, as noted above. Two patients with homozygous CaSR mutations escaped detection until adulthood (1, 28) and are particularly instructive. Both patients had serum  $\text{Ca}^{2+}$  of 15–17 mg/dl, hypermagnesemia (in one case; Ref. 1), overt hypophosphatemia, and a PTH level in the upper normal range in one case and frankly elevated in the other. There were decreases in the urinary calcium-to-creatinine clearance ratio comparable to FHH, and renal function was normal. The lack of the usual hypercalcemic renal complications in these cases suggests that several of the known effects of hypercalcemia on renal function, including hypercalciuria, impaired urinary concentrating capacity, and reduction in glomerular filtration rate (GFR) (in fact, FHH patients have a higher GFR than patients with PHPT) (101), can apparently be ascribed to the CaSR. The milder clinical presentation in these cases of “NSHPT” diagnosed in adulthood was likely due to mutant CaSRs with less functional impairment than is the norm in FHH (28).

The development of mice with targeted inactivation (“knockout” or KO) of the CaSR has provided useful models of FHH and NSHPT (68). The heterozygous CaSR KO mouse is a model of FHH, exhibiting mild hypercalcemia and elevations in PTH and relative hypocalciuria. This model provides strong evidence that a reduced complement of normal CaSRs can cause the  $\text{Ca}_o^{2+}$ -resistance of FHH because, based on immunohistochemistry or Western blotting, the levels of the CaSR in parathyroid and kidney were both reduced ~50% (68). Homozygous CaSR KO mice have an NSHPT phenotype, exhibiting severe hypercalcemia and hyperparathyroidism and dying within a few weeks of birth. The further use of these mice or those with conditional KO of the CaSR (26) in parathyroid and/or kidney will provide useful models to study the impact of



reduced CaSR expression on the function of parathyroid and kidney (and other tissues) *in vivo* and *in vitro*.

**Autosomal dominant hypoparathyroidism.** Patients with activating CaSR mutations have an often asymptomatic, autosomal dominant form of hypocalcemia/hypoparathyroidism (58, 67, 121). Some, however, manifest neuromuscular irritability, basal ganglia calcification, and seizures, complications observed in hypoparathyroidism of other causes (121). Patients with autosomal dominant hypoparathyroidism (ADH) (OMIM 601298) exhibit mild-moderate hypocalcemia, with low-normal or frankly subnormal PTH levels (119). Untreated ADH patients frequently have relative (i.e., inappropriately normal given their hypocalcemia) or absolute hypercalciuria (10, 121, 168). In several studies, urinary  $\text{Ca}^{2+}$  excretion in untreated ADH patients was about twice that in other forms of hypoparathyroidism (10, 121, 168). ADH, therefore, can be thought of as the mirror image of FHH, i.e., familial hypercalciuric hypocalcemia.

ADH is caused by heterozygous [or, in one case, homozygous (94)] activating mutations of the CaSR that increase the receptor's sensitivity to  $\text{Ca}_o^{2+}$  rather than, with rare exceptions, producing constitutive activation. Thus the  $\text{Ca}_o^{2+}$  homeostatic system is "reset," including CaSR-regulated PTH secretion, which exhibits a decrease in set point, to maintain and defend a subnormal serum  $\text{Ca}^{2+}$  level. Conceptually, one would anticipate a leftward shift in the relationship between  $\text{Ca}_o^{2+}$  and urinary  $\text{Ca}^{2+}$  excretion in ADH analogous to the reduced parathyroid set point. As noted above, some studies have found a higher level of urinary  $\text{Ca}^{2+}$  excretion in untreated ADH cases than in other types of hypoparathyroidism (121, 168). In contrast, Yamamoto et al. (169) also reported greater urinary  $\text{Ca}^{2+}$  excretion rate in untreated ADH patients than in other hypoparathyroid subjects but found that the relationship between the serum  $\text{Ca}^{2+}$  and urinary  $\text{Ca}^{2+}$ /creatinine during treatment did not differ between the two groups. It remains to be seen whether this observation will be replicated in other studies investigating  $\text{Ca}_o^{2+}$  sensing by the kidney in ADH.

Patients with ADH are prone to encounter renal complications during treatment with  $\text{Ca}^{2+}$  and vitamin D analogs aimed at increasing serum  $\text{Ca}^{2+}$  concentration toward normal (121), although there are no studies formally documenting this difference between ADH patients and other hypoparathyroid patients. These complications include nephrolithiasis, nephrocalcinosis, and reversible or, in some cases, irreversible renal impairment (118). One study (118) described four affected ADH patients who developed long-term, apparently irreversible decreases in renal function, with creatinine clearances of 30 ml/min or less during treatment with calcium and vitamin D supplementation. The renal complications developing during treatment of ADH may occur when serum  $\text{Ca}^{2+}$  concentration has been elevated close to or to within the lower range of normal but not higher. Treatment with  $\text{Ca}^{2+}$  supplements and  $1,25(\text{OH})_2\text{D}_3$  should only be used in symptomatic ADH patients; the goal is to elevate the serum  $\text{Ca}^{2+}$  just to the level that alleviates symptoms (93). Renal  $\text{Ca}^{2+}$  excretion should be carefully monitored to minimize the risk of renal complications. If raising serum  $\text{Ca}^{2+}$  to the level at which symptoms are alleviated cannot be achieved without frank hypercalciuria (generally  $4 \text{ mg} \cdot \text{kg}^{-1} \cdot 24 \text{ h}^{-1}$ ), coadministration of a hypocalciuric agent, such as a thiazide diuretic or injectable PTH administered once or twice daily, may be needed (168).

**Bartter syndrome with activating CaSR mutations.** Several patients have been reported with activating CaSR mutations and features of Bartter syndrome (a syndrome referred to as Bartter syndrome, type V) (159, 166). In addition to the typical features of ADH, these patients also exhibited hypokalemia with renal  $\text{K}^+$  wasting, hyperreninemia, and hyperaldosteronemia. These patients' mutant CaSRs exhibited markedly left-shifted  $\text{Ca}^{2+}$  concentration-response curves. It was postulated that these unusually active mutant CaSRs inhibited paracellular reabsorption of  $\text{Na}^+$ ,  $\text{Ca}^{2+}$ , and  $\text{Mg}^{2+}$  in TAL. Activation of the CaSR in typical ADH only enhances urinary calcium and magnesium excretion. However, with the Bartter variant, there is also apparently sufficient volume depletion to cause hyperreninemia, hyperaldosteronism, and resultant renal  $\text{K}^+$  loss.

#### *Inactivating and Activating Autoantibodies to CaSR*

About a dozen patients have been described with inactivating (83, 98, 116) or activating (79, 82) autoantibodies directed at the CaSR. Inactivating antibodies cause autoimmune hypocalciuric hypercalcemia (AHH). These patients have PTH-dependent hypercalcemia in the setting of other autoimmune conditions (e.g., Hashimoto thyroiditis) and, in most reported cases, exhibit hypocalciuria; all harbor anti-CaSR antibodies detected by various immunologic tests (e.g., ELISA, Western blot, etc.). In one study of four AHH patients, the anti-CaSR antibodies blunted CaSR-mediated activation of PLC and MAPK activity at physiological levels of  $\text{Ca}_o^{2+}$  (83). As expected for an inactivating antibody, PTH release from parathyroid cells incubated with patient sera was higher at any given level of  $\text{Ca}^{2+}$  relative to cells incubated with control sera. In another AHH patient, the anti-CaSR antibodies unexpectedly potentiated high  $\text{Ca}_o^{2+}$ -evoked PLC activity (i.e., had CaSR activating properties) but blunted MAPK activation (98), suggesting differential coupling of the antibody-bound receptor to these two signaling pathways. In some of the cases described to date, the autoantibodies likely interact with the CaSR in the kidney, thereby producing relative or absolute hypocalciuria despite hypercalcemia, as in FHH (83, 116). Thus inactivating antibodies can produce a clinical and biochemical picture similar to that caused by inactivating mutations in FHH. A small percentage (6.7%) of patients with PHPT harbored anti-CaSR antibodies in one study (27); the functional properties of these antibodies were not examined.

Anti-parathyroid antibodies and, more recently, anti-CaSR antibodies have been identified in patients with autoimmune or idiopathic hypoparathyroidism (for review, see Ref. 18). However, the functional properties of the anti-CaSR antibodies have been studied in only a few cases. Four patients to date have been shown to have antibodies that activate the CaSR with methods similar to those used to characterize inactivating antibodies (79, 82). These antibodies suppressed PTH secretion *in vitro* in association with activation of ERK1/2 and PLC, but the activity of these antibodies on the kidney, if any, is unknown.

#### *Impact of Acquired Forms of Hypercalcemia on CaSR*

Two common biochemical abnormalities involving the kidney in hypercalcemic patients are hypercalciuria and impaired urinary concentrating ability (17, 65). In hypercalcemic patients, activation of the renal CaSR by hypercalcemia will

reduce tubular reabsorption of  $\text{Ca}^{2+}$  in the TAL (65, 165). The resultant hypercalciuria is more marked in patients with etiologies of hypercalcemia leading to suppressed PTH than in those with hyperparathyroidism, since PTH stimulates  $\text{Ca}^{2+}$  reabsorption (this action is shared by PTHrP, but, nevertheless, patients with PTHrP-mediated hypercalcemia tend to have marked hypercalciuria) (149). Severe and prolonged hypercalcemia can eventually lead to nephrolithiasis, nephrocalcinosis, and renal impairment (17), but it is difficult to predict who will develop these complications and when. Hypercalcemia would also be expected to inhibit salt reabsorption in MTAL, thereby “washing out” the hypertonic medullary interstitium (65). The reduction in the countercurrent gradient, combined with the inhibitory effect of the CaSR on vasopressin-stimulated water reabsorption in the IMCD (142), will impair urinary concentrating ability. While diminished urinary concentrating capacity is a “classic” hypercalcemic complication, its true prevalence is uncertain. Impaired reabsorption of NaCl in the TAL combined with anorexia, nausea, and defective urinary concentrating ability likely all participate in varying measure in the volume depletion seen in some severely hypercalcemic patients. Whether other actions of hypercalcemia on the kidney, such as reduced GFR and renal blood flow (41), are CaSR mediated is unknown, although FHH patients have a higher GFR than comparably hypercalcemic patients with PHPT, suggesting a mediatory role of the CaSR in regulating GFR (103).

#### *CaSR in Kidney in Renal Disease*

Kidney disease alters the expression and function of the CaSR (and VDR) in the parathyroid, which, along with other factors, leads to secondary (and sometimes tertiary) hyperparathyroidism (55). This leads to deranged mineral ion and skeletal homeostasis and resultant morbidity, mortality, and expense to the health care system. The availability of calcimimetics that suppress secondary hyperparathyroidism in patients with stage 5 CKD (i.e., requiring dialysis) has provided a new addition to the therapeutic armamentarium in this setting (13, 36). The literature on this rapidly moving subject is large and has been reviewed in detail elsewhere (36, 55).

There has been little in the way of systematic study of the CaSR in the kidney in renal diseases and associated changes in CaSR-regulated renal function. A study utilizing experimentally induced renal failure in rats reported reduced renal CaSR expression but did not describe where the decrease took place (105). Reduced CaSR expression might contribute to the reduced renal calcium excretion in renal insufficiency as a result of a decrease in CaSR-evoked renal  $\text{Ca}^{2+}$  excretion.

#### *Impact of CaSR Polymorphisms on the Kidney*

Several studies have examined the possible impact of single nucleotide polymorphisms (SNPs) in the CaSR on  $\text{Ca}_0^{2+}$  homeostasis and related systems, i.e., blood pressure. Several are relevant to renal function in health and disease. For example, one study found that CaSR SNPs and related haplotypes (a haplotype in this setting is a sequence of SNPs on a single strand of DNA) were a determinant of the normal range of serum  $\text{Ca}^{2+}$  concentration in the population (143). This normal range is greater than that measured in any given individual. Indeed, certain haplotypes of SNPs at positions 986, 990, and

1011 in the CaSR's C tail were significantly associated with higher or lower serum ionized  $\text{Ca}^{2+}$  concentration within the normal range, and accounted for 17% of the variation in the normal range (143). In some cases, other groups have had discordant results with regard to the A986S polymorphism (15), perhaps because of small sample size or populations with differing frequencies of the SNPs. Clearly additional studies with larger sample sizes in well-characterized populations are needed.

The impact of CaSR SNPs on parameters related to renal function/dysfunction has also been studied. Having two glycine residues at position 990, instead of the more common alanine, has been associated with 1) lower PTH levels in hemodialysis patients (170), 2) hypercalciuria (161), and 3) greater suppressibility of PTH during induced hypercalcemia in hemodialysis patients (172). In another study, there was a greater risk of stone disease in patients with PHPT and the ACG haplotype at positions 986, 990, and 1011 (160). Some associations of SNPs with traits relevant to the kidney have involved noncoding SNPs (those present in introns or the promoter of the CaSR gene), perhaps by modifying receptor expression. In African Americans in the Indianapolis area, three SNPs were associated with systolic blood pressure and with urinary calcium excretion (75). These same investigators observed an interaction between CaSR, the CLCNKB (the basolateral chloride channel in the thick limb), and NKCC genes that contributed to variation in diastolic blood pressure, perhaps through changes in sodium and/or calcium transport in the TAL (76). These results indicate that the SNPs within the CaSR and other genes with which it interacts in the kidney could be a fruitful avenue of investigation. The availability of very large databases, with ~1,000,000 SNPs for genomewide association studies (GWAS) should be very helpful in this regard.

#### *CaSR-Based Therapeutics: Renal Implications*

The development of allosteric CaSR activators (“calcimimetics”) (112) and antagonists (“calcilytics”) (56) has enabled novel, CaSR-based therapy of disorders of calcium homeostasis. Cinacalcet hydrochloride (also known as Sensipar) was approved in 2004 by the FDA for treating severe secondary hyperparathyroidism in stage 5 kidney disease (13) as well as parathyroid cancer (145). Studies in experimental animals have suggested that administration of a calcimimetic in uremic animals reduces some of the long-term complications of this condition, including progression of renal impairment, atherosclerosis (74), and, in combination with vitamin D treatment, mortality (140). Studies are currently in progress in humans assessing the efficacy of the drug in decreasing cardiovascular disease and mortality. The drug also effectively lowers serum calcium concentration in mild primary hyperparathyroidism, but it has not received FDA approval for this indication, although it is approved for use in PHPT in Europe (117). The drug has been utilized in several other, “off-label” uses. Some may end up simply as “orphan” applications in very limited patient populations. Others may represent significant advances that will improve patient care in certain clinical settings. The drug has been used to control hypercalcemia/hyperparathyroidism in patients with renal insufficiency, other than in stage 5. One application is the use of the drug to treat hyperparathyroidism in CKD before dialysis. Although cinacalcet lowers PTH in this setting (45), it also modestly lowers serum calcium

and increases serum phosphate. The utility of the drug in this setting is currently unclear. A potentially valuable application is in the treatment of PTH-dependent hypercalcemia following renal transplantation (87). Cinacalcet restores normocalcemia in ~80% of such patients, with few adverse effects, except for occasional hypercalciuria (42) and mild, generally reversible, reductions in graft function in some patients.

Cinacalcet has been administered to patients with lithium-induced hyperparathyroidism (147), which is a form of PHPT. Although clinical experience with this application is very limited, correction of hypercalcemia has been observed. A drop in serum calcium has been observed in FHH after administration of cinacalcet (154), which is not unexpected since most mutant CaSRs are responsive to the drug. However, this application may be limited to rare FHH patients in whom lowering an unusually elevated PTH or serum calcium level or treatment of a potential complication, such as pancreatitis, is desirable, since the vast majority of FHH patients should simply be followed medically.

Cinacalcet has also been used in a limited number of patients with X-linked hypophosphatemia (2) or oncogenic osteomalacia (53), both of which have hypophosphatemia mediated by an excess of the phosphaturic hormone FGF-23. In this setting oral phosphate administration in four daily doses can induce secondary hyperparathyroidism, which aggravates the phosphate wasting owing to the phosphaturic action of PTH. In some cases, this secondary hyperparathyroidism progresses to hypercalcemic, “tertiary” hyperparathyroidism (139). The utility of the drug in this setting is to suppress this iatrogenic hyperparathyroidism, particularly when administered with 1,25(OH)<sub>2</sub>D<sub>3</sub>. Finally, in animal models of polycystic kidney disease, administration of a calcimimetic inhibits late-stage cyst growth, suggesting a possible use of the drug in human polycystic kidney disease (51). A striking feature of the use of cinacalcet to date is the lack of evidence of activation of the CaSR in other organs outside of the parathyroid, with the exception of the hypercalciuria in some patients receiving the drug after renal transplant, which could represent a direct effect on the CaSR in CTAL.

Ca<sub>o</sub><sup>2+</sup> receptor antagonists, so-called calcilytics, are also in development and are presently in clinical trials. The inhibitory action of the calcilytic on the CaSR has the consequence that a higher than normal level of Ca<sub>o</sub><sup>2+</sup> is required to suppress PTH levels (56, 111). That is, the CaSR reads normocalcemia as hypocalcemia and secretes a pulse of PTH. When exogenous PTH is injected once daily, it exerts an anabolic action on the skeleton, and it is the most effective anabolic drug available for treating osteoporosis (109). Clinical trials are investigating whether once- or twice-daily oral administration of a calcilytic has a similar therapeutic effect by releasing a pulse of endogenous PTH. It is also conceivable that a longer-acting calcilytic could be used in the treatment of ADH or ADH with Bartter features. Right-shifting the activation of the mutant CaSR by extracellular Ca<sup>2+</sup> could produce a more normal set point for Ca<sub>o</sub><sup>2+</sup>-regulated PTH release and urinary Ca<sup>2+</sup> excretion in this setting. An analogous approach to treating hypercalciuric renal stones would be the use of a calcilytic with some specificity for the kidney, so as to induce “FHH of the kidney,” thereby reducing urinary calcium excretion without stimulating PTH release.

### Conclusions and Future Directions

Recent evidence suggests that the kidney CaSR directly regulates a variety of aspects of renal fluid and electrolyte handling, urinary acidification, and blood pressure control. In addition, there are a number of inherited and acquired conditions in which the level of expression and/or function of the CaSR are altered, thereby directly or indirectly impacting the function of the kidney. Current CaSR therapeutics (e.g., calcimimetics) on the market are proving very effective at modulating receptor function in patients with primary and secondary hyperparathyroidism. Future studies will need to investigate the application of these drugs to other conditions with abnormal Ca<sub>o</sub><sup>2+</sup> sensing by the parathyroid as well as whether it is possible to develop CaSR therapeutics with some specificity for the kidney, thereby enabling modulation of abnormal renal Ca<sub>o</sub><sup>2+</sup> sensing.

### ACKNOWLEDGMENTS

This article celebrates the life and the scientific achievements of our friend, the late Dr. Steven Hebert. Other articles in this series include Gamba G. The thiazide-sensitive Na<sup>+</sup>-Cl<sup>-</sup> cotransporter: molecular biology, functional properties, and regulation by WNKs. *Am J Physiol Renal Physiol* 297: F838–F848, 2009 and Welling PA, Ho K. A comprehensive guide to the ROMK potassium channel: form and function in health and disease. *Am J Physiol Renal Physiol* 297: F849–F863, 2009.

### GRANTS

D. Riccardi thanks the Biotechnology and Biological Sciences Research Council (BBSRC; grant no. BB/D01591X) for funding her work and the members of her laboratory for stimulating discussions. E. M. Brown thanks the National Institute of Diabetes and Digestive and Kidney Diseases for current grant support (DK-078331).

### DISCLOSURES

D. Riccardi received a grant from Amgen. E. M. Brown has a financial interest in the calcimimetic cinacalcet.

### REFERENCES

1. Aida K, Koishi S, Inoue M, Nakazato M, Tawata M, Onaya T. Familial hypocalciuric hypercalcemia associated with mutation in the human Ca<sup>2+</sup>-sensing receptor gene. *J Clin Endocrinol Metab* 80: 2594–2598, 1995.
2. Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. *Clin J Am Soc Nephrol* 3: 658–664, 2008.
3. Amlal H, Paillard M, Bichara M. Cl<sup>-</sup>-dependent NH<sub>4</sub><sup>+</sup> transport mechanisms in medullary thick ascending limb cells. *Am J Physiol Cell Physiol* 267: C1607–C1615, 1994.
4. Attie MF, Gill J Jr, Stock JL, Spiegel AM, Downs RW Jr, Levine MA, Marx SJ. Urinary calcium excretion in familial hypocalciuric hypercalcemia. Persistence of relative hypocalciuria after induction of hypoparathyroidism. *J Clin Invest* 72: 667–676, 1983.
5. Auwerx J, Demedts M, Bouillon R. Altered parathyroid set point to calcium in familial hypocalciuric hypercalcaemia. *Acta Endocrinologica (Copenh)* 106: 215–218, 1984.
6. Awata H, Huang C, Handlogten ME, Miller RT. Interaction of the calcium-sensing receptor and filamin, a potential scaffolding protein. *J Biol Chem* 276: 34871–34879, 2001.
7. Ba J, Brown D, Friedman PA. Calcium-sensing receptor regulation of PTH-inhibitable proximal tubule phosphate transport. *Am J Physiol Renal Physiol* 285: F1233–F1243, 2003.
8. Bai M, Pearce SH, Kifor O, Trivedi S, Stauffer UG, Thakker RV, Brown EM, Steinmann B. In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca<sup>2+</sup>-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. *J Clin Invest* 99: 88–96, 1997.

9. **Barajas L.** Anatomy of the juxtaglomerular apparatus. *Am J Physiol Renal Fluid Electrolyte Physiol* 237: F333–F343, 1979.
10. **Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB Jr.** Mutations in the  $\text{Ca}^{2+}$ -sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. *Hum Mol Genet* 5: 601–606, 1996.
11. **Beierwaltes WH.** The role of calcium in the regulation of renin secretion. *Am J Physiol Renal Physiol* 298: F1–F11, 2010.
12. **Blankenship KA, Williams JJ, Lawrence MS, McLeish KR, Dean WL, Arthur JM.** The calcium-sensing receptor regulates calcium absorption in MDCK cells by inhibition of PMCA. *Am J Physiol Renal Physiol* 280: F815–F822, 2001.
13. **Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG.** Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. *N Engl J Med* 350: 1516–1525, 2004.
14. **Boim MA, Ho K, Shuck ME, Bienkowski MJ, Block JH, Slightom JL, Yang Y, Brenner BM, Hebert SC.** ROMK inwardly rectifying ATP-sensitive  $\text{K}^+$  channel. II. Cloning and distribution of alternative forms. *Am J Physiol Renal Fluid Electrolyte Physiol* 268: F1132–F1140, 1995.
15. **Bollerslev J, Wilson SG, Dick IM, Devine A, Dhaliwal SS, Prince RL.** Calcium-sensing receptor gene polymorphism A986S does not predict serum calcium level, bone mineral density, calcaneal ultrasound indices, or fracture rate in a large cohort of elderly women. *Calcif Tissue Int* 74: 12–17, 2004.
16. **Brauner-Osborne H, Wellendorph P, Jensen AA.** Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. *Curr Drug Targets* 8: 169–184, 2007.
17. **Bringham FR, Demay MB, Kronenberg HM.** Hormones and disorders of mineral metabolism. In: *Williams's Textbook of Endocrinology* (9th ed.), edited by Wilson JD, Foster DW, Kronenberg HM, Larsen PR. Philadelphia: Saunders, 1998, p. 1155–1209.
18. **Brown EM.** Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism. *Endocrinol Metab Clin North Am* 38: 437–445, 2009.
19. **Brown EM.** Clinical lessons from the calcium-sensing receptor. *Nat Clin Pract Endocrinol Metab* 3: 122–133, 2007.
20. **Brown EM.** Extracellular  $\text{Ca}^{2+}$  sensing, regulation of parathyroid cell function, and role of  $\text{Ca}^{2+}$  and other ions as extracellular (first) messengers. *Physiol Rev* 71: 371–411, 1991.
21. **Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC.** Cloning and characterization of an extracellular  $\text{Ca}^{2+}$ -sensing receptor from bovine parathyroid. *Nature* 366: 575–580, 1993.
22. **Canaff L, Hendy GN.** Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. *J Biol Chem* 277: 30337–30350, 2002.
23. **Canaff L, Zhou X, Hendy GN.** The proinflammatory cytokine, interleukin-6, up-regulates calcium-sensing receptor gene transcription via Stat1/3 and Sp1/3. *J Biol Chem* 283: 13586–13600, 2008.
24. **Capasso G, Rizzo M, Pica A, Di Maio FS, Moe OW, Alpern RJ, De Santo NG.** Bicarbonate reabsorption and NHE-3 expression: abundance and activity are increased in Henle's loop of remnant rats. *Kidney Int* 62: 2126–2135, 2002.
25. **Carling T, Szabo E, Bai M, Ridefelt P, Westin G, Gustavsson P, Trivedi S, Hellman P, Brown EM, Dahl N, Rastad J.** Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. *J Clin Endocrinol Metab* 85: 2042–2047, 2000.
26. **Chang W, Tu C, Chen TH, Bikle D, Shoback D.** The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. *Sci Signal* 1: ra1, 2008.
27. **Charrie A, Chikh K, Peix JL, Berger N, Decaussin M, Veber S, Bienvenu J, Lifante JC, Fabien N.** Calcium-sensing receptor autoantibodies in primary hyperparathyroidism. *Clin Chim Acta* 406: 94–97, 2009.
28. **Chikatsu N, Fukumoto S, Suzawa M, Tanaka Y, Takeuchi Y, Takeda S, Tamura Y, Matsumoto T, Fujita T.** An adult patient with severe hypercalcemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium-sensing receptor. *Clin Endocrinol (Oxf)* 50: 537–543, 1999.
29. **Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Brixen K, Mosekilde L.** Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a follow-up study on methods. *Clin Endocrinol (Oxf)* 69: 713–720, 2008.
30. **Cole DE, Janicic N, Salisbury SR, Hendy GN.** Neonatal severe hyperparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: multiple different phenotypes associated with an inactivating Alu insertion mutation of the calcium-sensing receptor gene. *Am J Med Genet* 71: 202–210, 1997. [Erratum. *Am J Med Genet* 72: October 17, 1997, p. 251–252.]
31. **Cole DE, Quamme GA.** Inherited disorders of renal magnesium handling. *J Am Soc Nephrol* 11: 1937–1947, 2000.
32. **Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ.** Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. *J Clin Endocrinol Metab* 83: 1083–1088, 1998.
33. **Conigrave AD, Mun HC, Brennan SC.** Physiological significance of L-amino acid sensing by extracellular  $\text{Ca}^{2+}$ -sensing receptors. *Biochem Soc Trans* 35: 1195–1198, 2007.
34. **Cooper L, Wertheimer J, Levey R, Brown E, Leboff M, Wilkinson R, Anast CS.** Severe primary hyperparathyroidism in a neonate with two hypercalcemic parents: management with parathyroidectomy and heterotopic autotransplantation. *Pediatrics* 78: 263–268, 1986.
35. **Di Stefano A, Wittner M, Nitschke R, Braitsch R, Greger R, Bailly C, Amiel C, Roinel N, de Rouffignac C.** Effects of parathyroid hormone and calcitonin on  $\text{Na}^+$ ,  $\text{Cl}^-$ ,  $\text{K}^+$ ,  $\text{Mg}^{2+}$ , and  $\text{Ca}^{2+}$  transport in cortical and medullary thick ascending limbs of mouse kidney. *Pflügers Arch* 417: 161–167, 1990.
36. **Drueke TB, Ritz E.** Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. *Clin J Am Soc Nephrol* 4: 234–241, 2009.
37. **Dvorak MM, Siddiqua A, Ward DT, Carter DH, Dallas SL, Nemeth EF, Riccardi D.** Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. *Proc Natl Acad Sci USA* 101: 5140–5145, 2004.
38. **Eftekhari F, Yousefzadeh D.** Primary infantile hyperparathyroidism: clinical, laboratory, and radiographic features in 21 cases. *Skeletal Radiol* 8: 201–208, 1982.
39. **Egbuna O, Quinn S, Kantham L, Butters R, Pang J, Pollak M, Goltzman D, Brown E.** The full-length calcium-sensing receptor dampens the calcemic response to 1 $\alpha$ ,25(OH) $_2$  vitamin D $_3$  in vivo independent of parathyroid hormone. *Am J Physiol Renal Physiol* 297: F720–F728, 2009.
40. **el-Hajj Fuleihan G, Seifter J, Scott J, Brown EM.** Calcium-regulated renal calcium handling in healthy men: relationship to sodium handling. *J Clin Endocrinol Metab* 83: 2366–2372, 1998.
41. **Epstein F.** Calcium and the kidney. *Am J Med* 45: 700–713, 1968.
42. **Espósito L, Rostaing L, Gennero I, Mehrenberger M, Durand D, Kamar N.** Hypercalciuria induced by a high dose of cinacalcet in a renal-transplant recipient. *Clin Nephrol* 68: 245–248, 2007.
43. **Fan GF, Ray K, Zhao XM, Goldsmith PK, Spiegel AM.** Mutational analysis of the cysteines in the extracellular domain of the human  $\text{Ca}^{2+}$  receptor: effects on cell surface expression, dimerization and signal transduction. *FEBS Lett* 436: 353–356, 1998.
44. **Farajov EI, Morimoto T, Aslanova UF, Kumagai N, Sugawara N, Kondo Y.** Calcium-sensing receptor stimulates luminal  $\text{K}^+$ -dependent  $\text{H}^+$  excretion in medullary thick ascending limbs of Henle's loop of mouse kidney. *Tohoku J Exp Med* 216: 7–15, 2008.
45. **Fournier A, Shahapuni I, Harbouche L, Monge M.** Calcimimetics for predialysis patients? *Am J Kidney Dis* 47: 196–107, 2006.
46. **Fox L, Sadowsky J, Pringle KP, Kidd A, Murdoch J, Cole DE, Wiltshire E.** Neonatal hyperparathyroidism and pamidronate therapy in an extremely premature infant. *Pediatrics* 120: e1350–e1354, 2007.
47. **Fray JC, Park CS, Valentine AN.** Calcium and the control of renin secretion. *Endocr Rev* 8: 53–93, 1987.
48. **Friedman PA.** Calcium transport in the kidney. *Curr Opin Nephrol Hypertens* 8: 589–595, 1999.
49. **Friedman PA, Coutermarsh BA, Kennedy SM, Gesek FA.** Parathyroid hormone stimulation of calcium transport is mediated by dual signaling mechanisms involving protein kinase A and protein kinase C. *Endocrinology* 137: 13–20, 1996.

50. **Garfia B, Canadillas S, Canalejo A, Luque F, Siendones E, Quesada M, Almaden Y, Aguilera-Tejero E, Rodriguez M.** Regulation of parathyroid vitamin D receptor expression by extracellular calcium. *J Am Soc Nephrol* 13: 2945–2952, 2002.
51. **Gattone VH 2nd, Chen NX, Sinderson RM, Seifert MF, Duan D, Martin D, Henley C, Moe SM.** Calcimimetic inhibits late-stage cyst growth in ADPKD. *J Am Soc Nephrol* 20: 1527–1532, 2009.
52. **Geibel JP, Hebert SC.** The functions and roles of the extracellular  $\text{Ca}^{2+}$ -sensing receptor along the gastrointestinal tract. *Annu Rev Physiol* 71: 205–217, 2009.
53. **Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS, Collins MT.** Cinacalcet in the management of tumor-induced osteomalacia. *J Bone Miner Res* 22: 931–937, 2007.
54. **Good DW, Watts 3rd BA, George T, Meyer JW, Shull GE.** Transepithelial  $\text{HCO}_3^-$  absorption is defective in renal thick ascending limbs from  $\text{Na}^+/\text{H}^+$  exchanger NHE1 null mutant mice. *Am J Physiol Renal Physiol* 287: F1244–F1249, 2004.
55. **Goodman WG, Quarles LD.** Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. *Kidney Int* 74: 276–288, 2008.
56. **Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J.** Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. *J Clin Invest* 105: 1595–1604, 2000.
57. **Harris SS, D'Ercole AJ.** Neonatal hyperparathyroidism: the natural course in the absence of surgical intervention. *Pediatrics* 83: 53–56, 1989.
58. **Hauache OM.** Extracellular calcium-sensing receptor: structural and functional features and association with diseases. *Braz J Med Biol Res* 34: 577–584, 2001.
59. **Heath D.** Familial benign hypercalcemia. *Trends Endocrinol Metab* 1: 6–9, 1989.
60. **Heath DA.** Clinical manifestations of abnormalities of the calcium sensing receptor. *Clin Endocrinol (Oxf)* 48: 257–8, 1998.
61. **Heath DA.** Familial hypocalciuric hypercalcemia. In: *The Parathyroids*, edited by Bilezikian JP, Marcus R, Levine MA. New York: Raven, 1994, p. 699–710.
62. **Heath H 3rd.** Familial benign (hypocalciuric) hypercalcemia. A troublesome mimic of mild primary hyperparathyroidism. *Endocrinol Metab Clin North Am* 18: 723–740, 1989.
63. **Heath H, 3rd, Jackson CE, Otterud B, Leppert MF.** Genetic linkage analysis in familial benign (hypocalciuric) hypercalcemia: evidence for locus heterogeneity. *Am J Hum Genet* 53: 193–200, 1993.
64. **Hebert SC.** Molecular mechanisms. *Semin Nephrol* 19: 504–523, 1999.
65. **Hebert SC, Brown EM, Harris HW.** Role of the  $\text{Ca}^{2+}$ -sensing receptor in divalent mineral ion homeostasis. *J Exp Biol* 200: 295–302, 1997.
66. **Hebert SC, Riccardi D, Geibel J.** The calcium-sensing receptor. In: *The Kidney: Physiology and Pathophysiology* (4th ed.), edited by Alpern RJ, Hebert SC. Amsterdam: Elsevier, 2007, p. 1785–1882.
67. **Hendy GN, D'Souza-Li L, Yang B, Canaff L, Cole DE.** Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. *Hum Mutat* 16: 281–296, 2000.
68. **Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, Brown EM, Seidman JG, Seidman CE.** A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. *Nat Genet* 11: 389–394, 1995.
69. **Hoenderop JG, Bindels RJ.** Epithelial  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  channels in health and disease. *J Am Soc Nephrol* 16: 15–26, 2005.
70. **Hoenderop JG, Chon H, Gkika D, Bluyssen HA, Holstege FC, St-Arnaud R, Braam B, Bindels RJ.** Regulation of gene expression by dietary  $\text{Ca}^{2+}$  in kidneys of 25-hydroxyvitamin D3-1 alpha-hydroxylase knockout mice. *Kidney Int* 65: 531–539, 2004.
71. **Hu J, Spiegel AM.** Naturally occurring mutations in the extracellular  $\text{Ca}^{2+}$ -sensing receptor: implications for its structure and function. *Trends Endocrinol Metab* 14: 282–288, 2003.
72. **Huang C, Miller RT.** The calcium-sensing receptor and its interacting proteins. *J Cell Mol Med* 11: 923–934, 2007.
73. **Ikari A, Okude C, Sawada H, Sasaki Y, Yamazaki Y, Sugatani J, Degawa M, Miwa M.** Activation of a polyvalent cation-sensing receptor decreases magnesium transport via claudin-16. *Biochim Biophys Acta* 1778: 283–290, 2008.
74. **Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentavri R, Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Kamel S, Lacour B, Druke TB, Massy ZA.** The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE $^{-/-}$ ) mice. *Atherosclerosis* 205: 55–62, 2009.
75. **Jung J, Foroud TM, Eckert GJ, Flury-Wetherill L, Edenberg HJ, Xuei X, Zaidi SA, Pratt JH.** Association of the calcium-sensing receptor gene with blood pressure and urinary calcium in African-Americans. *J Clin Endocrinol Metab* 94: 1042–1048, 2009.
76. **Jung J, Sun B, Kwon D, Koller DL, Foroud TM.** Allelic-based gene-gene interaction associated with quantitative traits. *Genet Epidemiol* 33: 332–343, 2009.
77. **Kallay E, Wrba F, Cross HS.** Dietary calcium and colon cancer prevention. *Forum Nutr* 56: 188–190, 2003.
78. **Kantham L, Quinn SJ, Egbuna OI, Baxi K, Butters R, Pang JL, Pollak MR, Goltzman D, Brown EM.** The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. *Am J Physiol Endocrinol Metab* 297: E915–E923, 2009.
79. **Kemp EH, Gavilas NG, Krohn KJ, Brown EM, Watson PF, Weetman AP.** Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1. *J Clin Endocrinol Metab* 94: 4749–4756, 2009.
80. **Khosla S, Ebeling PR, Firek AF, Burritt MM, Kao PC, Heath Hd.** Calcium infusion suggests a “set-point” abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. *J Clin Endocrinol Metab* 76: 715–720, 1993.
81. **Kifor O, Diaz R, Butters R, Kifor I, Brown EM.** The calcium-sensing receptor is localized in caveolin-rich plasma membrane domains of bovine parathyroid cells. *J Biol Chem* 273: 21708–21713, 1998.
82. **Kifor O, McElduff A, LeBoff MS, Moore FD Jr, Butters R, Gao P, Cantor TL, Kifor I, Brown EM.** Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. *J Clin Endocrinol Metab* 89: 548–556, 2004.
83. **Kifor O, Moore FD Jr, Delaney M, Garber J, Hendy GN, Butters R, Gao P, Cantor TL, Kifor I, Brown EM, Wysolmerski J.** A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. *J Clin Endocrinol Metab* 88: 60–72, 2003.
84. **Knepper MA.**  $\text{NH}_4^+$  transport in the kidney. *Kidney Int Suppl* 33: S95–S102, 1991.
85. **Kobayashi M, Tanaka H, Tsuzuki K, Tsuyuki M, Igaki H, Ichinose Y, Aya K, Nishioka N, Seino Y.** Two novel missense mutations in calcium-sensing receptor gene associated with neonatal severe hyperparathyroidism. *J Clin Endocrinol Metab* 82: 2716–2719, 1997.
86. **Kovacs CS, Ho-Pao CL, Hunzelman JL, Lanske B, Fox J, Seidman JG, Seidman CE, Kronenberg HM.** Regulation of murine fetal-placental calcium metabolism by the calcium-sensing receptor. *J Clin Invest* 101: 2812–2820, 1998.
87. **Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG.** The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. *Nephrol Dial Transplant* 20: 1311–1314, 2005.
88. **Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, Morikawa K.** Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. *Nature* 407: 971–977, 2000.
89. **Law WM Jr, Bollman S, Kumar R, Heath IIIH.** Vitamin D metabolism in familial benign hypercalcemia (hypocalciuric hypercalcemia) differs from that in primary hyperparathyroidism. *J Clin Endocrinol Metab* 58: 744–747, 1984.
90. **Law WM Jr, Carney JA, Heath H III.** Parathyroid glands in familial benign hypercalcemia (familial hypocalciuric hypercalcemia). *Am J Med* 76: 1021–1026, 1984.
91. **Law WM Jr, Heath H III.** Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families. *Ann Int Med* 105: 511–519, 1985.
92. **Levi R, Ben-Dov IZ, Lavi-Moshayoff V, Dinur M, Martin D, Naveh-Manly T, Silver J.** Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. *J Am Soc Nephrol* 17: 107–112, 2006.
93. **Lienhardt A, Bai M, Lagarde JP, Rigaud M, Zhang Z, Jiang Y, Kottler ML, Brown EM, Garabedian M.** Activating mutations of the

- calcium-sensing receptor: management of hypocalcemia. *J Clin Endocrinol Metab* 86: 5313–5323, 2001.
94. **Lienhardt A, Garabedian M, Bai M, Sinding C, Zhang Z, Lagarde JP, Boulesteix J, Rigaud M, Brown EM, Kottler ML.** A large homozygous or heterozygous in-frame deletion within the calcium-sensing receptor's carboxylterminal cytoplasmic tail that causes autosomal dominant hypocalcemia. *J Clin Endocrinol Metab* 85: 1695–1702, 2000.
  95. **Lloyd SE, Pannett AA, Dixon PH, Whyte MP, Thakker RV.** Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13. *Am J Hum Genet* 64: 189–195, 1999.
  96. **Maillard MP, Tedjani A, Perregaux C, Burnier M.** Calcium-sensing receptors modulate renin release in vivo and in vitro in the rat. *J Hypertens* 27: 1980–1987, 2009.
  97. **Maiti A, Beckman MJ.** Extracellular calcium is a direct effector of VDR levels in proximal tubule epithelial cells that counter-balances effects of PTH on renal vitamin D metabolism. *J Steroid Biochem Mol Biol* 103: 504–508, 2007.
  98. **Makita N, Sato J, Manaka K, Shoji Y, Oishi A, Hashimoto M, Fujita T, Iiri T.** An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations. *Proc Natl Acad Sci USA* 104: 5443–5448, 2007.
  99. **Mamillapalli R, VanHouten J, Zawalich W, Wysolmerski J.** Switching of G-protein usage by the calcium-sensing receptor reverses its effect on parathyroid hormone-related protein secretion in normal versus malignant breast cells. *J Biol Chem* 283: 24435–24447, 2008.
  100. **Marx S, Lasker R, Brown E, Fitzpatrick L, Sweezey N, Goldbloom R, Gillis D, Cole D.** Secretory dysfunction in parathyroid cells from a neonate with severe primary hyperparathyroidism. *J Clin Endocrinol Metab* 62: 445–449, 1986.
  101. **Marx S, Spiegel A, Brown E, Koehler J, Gardner D, Brennan M, Aurbach G.** Divalent cation metabolism. Familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. *Am J Med* 65: 235–242, 1978.
  102. **Marx SJ, Attie MF, Levine MA, Spiegel AM, Downs RW Jr, Lasker RD.** The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. *Medicine (Baltimore)* 60: 397–412, 1981.
  103. **Marx SJ, Attie MF, Stock JL, Spiegel AM, Levine MA.** Maximal urine-concentrating ability: familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. *J Clin Endocrinol Metab* 52: 736–740, 1981.
  104. **Marx SJ, Fraser D, Rapoport A.** Familial hypocalciuric hypercalcemia. Mild expression of the gene in heterozygotes and severe expression in homozygotes. *Am J Med* 78: 15–22, 1985.
  105. **Mathias R, Nguyen H, Zhang M, Portale A.** Expression of the renal calcium-sensing receptor is reduced in rats with experimental chronic renal insufficiency (Abstract). *J Bone Miner Res* 12: S326, 1997.
  106. **Mentaverri R, Yano S, Chattopadhyay N, Petit L, Kifor O, Kamel S, Terwilliger EF, Brazier M, Brown EM.** The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. *FASEB J* 20: 2562–2564, 2006.
  107. **Motoyama HI, Friedman PA.** Calcium-sensing receptor regulation of PTH-dependent calcium absorption by mouse cortical ascending limbs. *Am J Physiol Renal Physiol* 283: F399–F406, 2002.
  108. **Nedvetsky PI, Tamma G, Beulshausen S, Valenti G, Rosenthal W, Klusmann E.** Regulation of aquaporin-2 trafficking. *Handb Exp Pharmacol*: 133–157, 2009.
  109. **Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.** Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 344: 1434–1441, 2001.
  110. **Nemeth E, Scarpa A.** Rapid mobilization of cellular  $Ca^{2+}$  in bovine parathyroid cells by external divalent cations. *J Biol Chem* 260: 5188–5196, 1987.
  111. **Nemeth EF, Fox J, Delmar EG, Steffey ME, Lambert LD, Conklin RL, Bhatnagar PK, Gowen M.** Stimulation of parathyroid hormone secretion by a small molecule antagonist of the calcium receptor (Abstract). *J Bone Miner Res* 23: S156, 1998.
  112. **Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF.** Calcimimetics with potent and selective activity on the parathyroid calcium receptor. *Proc Natl Acad Sci USA* 95: 4040–4045, 1998.
  113. **Nielsen PK, Rasmussen AK, Butters R, Feldt-Rasmussen U, Bendtzen K, Diaz R, Brown EM, Olgaard K.** Inhibition of PTH secretion by interleukin-1beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA. *Biochem Biophys Res Commun* 238: 880–885, 1997.
  114. **Ortiz-Capisano MC, Liao TD, Ortiz PA, Beierwaltes WH.** Calcium-dependent phosphodiesterase 1C inhibits renin release from isolated juxtaglomerular cells. *Am J Physiol Regul Integr Comp Physiol* 297: R1469–R1476, 2009.
  115. **Ortiz-Capisano MC, Ortiz PA, Garvin JL, Harding P, Beierwaltes WH.** Expression and function of the calcium-sensing receptor in juxtaglomerular cells. *Hypertension* 50: 737–743, 2007.
  116. **Pallais JC, Kifor O, Chen YB, Slovik D, Brown EM.** Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. *N Engl J Med* 351: 362–369, 2004.
  117. **Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D.** Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. *J Clin Endocrinol Metab* 90: 135–141, 2005.
  118. **Pearce S, Coulthard M, Kendall-Taylor P, Thakker R.** Autosomal dominant hypocalcemia associated with a mutation in the calcium-sensing receptor (Abstract). *J Bone Miner Res* 10: S176, 1995.
  119. **Pearce SH.** Clinical disorders of extracellular calcium-sensing and the molecular biology of the calcium-sensing receptor. *Ann Med* 34: 201–206, 2002.
  120. **Pearce SH, Trump D, Wooding C, Besser GM, Chew SL, Grant DB, Heath DA, Hughes IA, Paterson CR, Whyte MP.** Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. *J Clin Invest* 96: 2683–2692, 1995.
  121. **Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown EM, Thakker RV.** A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. *N Engl J Med* 335: 1115–1122, 1996.
  122. **Pearce SH, Wooding C, Davies M, Tollefsen SE, Whyte MP, Thakker RV.** Calcium-sensing receptor mutations in familial hypocalciuric hypercalcemia with recurrent pancreatitis. *Clin Endocrinol (Oxf)* 45: 675–680, 1996.
  123. **Pi M, Faber P, Ekema G, Jackson PD, Ting A, Wang N, Fontilla-Poole M, Mays RW, Brunden KR, Harrington JJ, Quarles LD.** Identification of a novel extracellular cation-sensing G-protein-coupled receptor. *J Biol Chem* 280: 40201–40209, 2005.
  124. **Pidasheva S, Grant M, Canaff L, Ercan O, Kumar U, Hendy GN.** Calcium-sensing receptor dimerizes in the endoplasmic reticulum: biochemical and biophysical characterization of CASR mutants retained intracellularly. *Hum Mol Genet* 15: 2200–2209, 2006.
  125. **Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, Park J, Hebert SC, Seidman CE, Seidman JG.** Autosomal dominant hypocalcaemia caused by a  $Ca^{2+}$ -sensing receptor gene mutation. *Nat Genet* 8: 303–307, 1994.
  126. **Pollak MR, Chou YH, Marx SJ, Steinmann B, Cole DE, Brandi ML, Papapoulos SE, Menko FH, Hendy GN, Brown EM.** Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. *J Clin Invest* 93: 1108–1112, 1994.
  127. **Procino G, Mastrofrancesco L, Mira A, Tamma G, Carosino M, Emma F, Svelto M, Valenti G.** Aquaporin 2 and apical calcium-sensing receptor: new players in polyuric disorders associated with hypercalciuria. *Semin Nephrol* 28: 297–305, 2008.
  128. **Quamme GA.** Effect of hypercalcemia on renal tubular handling of calcium and magnesium. *Can J Physiol Pharmacol* 60: 1275–1280, 1982.
  129. **Quamme GA, de Rouffignac C.** Epithelial magnesium transport and regulation by the kidney. *Front Biosci* 5: D694–D711, 2000.
  130. **Quentin F, Eladari D, Frische S, Cambillau M, Nielsen S, Alper SL, Paillard M, Chambrey R.** Regulation of the  $Cl^{-}/HCO_3^{-}$  exchanger AE2 in rat thick ascending limb of Henle's loop in response to changes in acid-base and sodium balance. *J Am Soc Nephrol* 15: 2988–2997, 2004.
  131. **Quinn SJ, Bai M, Brown EM.** pH sensing by the calcium-sensing receptor. *J Biol Chem* 279: 37241–37249, 2004.
  132. **Quinn SJ, Kifor O, Trivedi S, Diaz R, Vassilev P, Brown E.** Sodium and ionic strength sensing by the calcium receptor. *J Biol Chem* 273: 19579–19586, 1998.
  133. **Renkema KY, Velic A, Dijkman HB, Verkaart S, van der Kemp AW, Nowik M, Timmermans K, Doucet A, Wagner CA, Bindels RJ, Hoen-**

- derop JG.** The calcium-sensing receptor promotes urinary acidification to prevent nephrolithiasis. *J Am Soc Nephrol* 20: 1705–1713, 2009.
134. **Rhone DP.** Primary neonatal hyperparathyroidism. Report of a case and review of the literature. *Am J Clin Pathol* 64: 488–499, 1975.
135. **Riccardi D, Hall AE, Chattopadhyay N, Xu JZ, Brown EM, Hebert SC.** Localization of the extracellular  $\text{Ca}^{2+}$ /polyvalent cation-sensing protein in rat kidney. *Am J Physiol Renal Physiol* 274: F611–F622, 1998.
136. **Riccardi D, Lee WS, Lee K, Segre GV, Brown EM, Hebert SC.** Localization of the extracellular  $\text{Ca}^{2+}$ -sensing receptor and PTH/PTHrP receptor in rat kidney. *Am J Physiol Renal Fluid Electrolyte Physiol* 271: F951–F956, 1996.
137. **Riccardi D, Park J, Lee WS, Gamba G, Brown EM, Hebert SC.** Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. *Proc Natl Acad Sci USA* 92: 131–135, 1995.
138. **Riccardi D, Traebert M, Ward DT, Kaissling B, Biber J, Hebert SC, Murer H.** Dietary phosphate and parathyroid hormone alter the expression of the calcium-sensing receptor (CaR) and the  $\text{Na}^+$ -dependent  $\text{P}_i$  transporter (NaPi-2) in the rat proximal tubule. *Pflügers Arch* 441: 379–387, 2000.
139. **Rivkees SA, El-Hajj Fuleihan G, Brown EM, Crawford JD.** Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. *J Clin Endocrinol Metab* 75: 1514–1518, 1992.
140. **Rodriguez M, Aguilera-Tejero E, Mendoza FJ, Guerrero F, Lopez I.** Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease. *Kidney Int Suppl*: S50–S54, 2008.
141. **Sands JM, Flores FX, Kato A, Baum MA, Brown EM, Ward DT, Hebert SC, Harris HW.** Vasopressin-elicited water and urea permeabilities are altered in IMCD in hypercalcemic rats. *Am J Physiol Renal Physiol* 274: F978–F985, 1998.
142. **Sands JM, Naruse M, Baum M, Jo I, Hebert SC, Brown EM, Harris HW.** Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. *J Clin Invest* 99: 1399–1405, 1997.
143. **Scillitani A, Guarnieri V, DE Geronimo S, Muscarella LA, Battista C, D'Agruma L, Bertoldo F, Florio C, Minisola S, Hendy GN, Cole DE.** Blood ionized calcium is associated with clustered polymorphisms in the carboxyl-terminal tail of the calcium-sensing receptor. *J Clin Endocrinol Metab* 89: 5634–5638, 2004.
144. **Silve C, Petrel C, Leroy C, Bruel H, Mallet E, Rognan D, Ruat M.** Delineating a  $\text{Ca}^{2+}$  binding pocket within the venus flytrap module of the human calcium-sensing receptor. *J Biol Chem* 280: 37917–37923, 2005.
145. **Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP.** Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. *J Clin Endocrinol Metab* 92: 3803–3808, 2007.
146. **Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A, Colussi G, Rodriguez-Soriano J, McCreddie D, Milford D, Sanjad S, Lifton RP.** Paracellin-1, a renal tight junction protein required for paracellular  $\text{Mg}^{2+}$  resorption. *Science* 285: 103–106, 1999.
147. **Sloand JA, Shelly MA.** Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. *Am J Kidney Dis* 48: 832–837, 2006.
148. **Spiegel AM, Harrison HE, Marx SJ, Brown EM, Aurbach GD.** Neonatal primary hyperparathyroidism with autosomal dominant inheritance. *J Pediatr* 90: 269–272, 1977.
149. **Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE.** Biochemical evaluation of patients with cancer-associated hypercalcemia. Evidence for humoral and non-humoral groups. *N Engl J Med* 303: 1377–1380, 1980.
150. **Strewler GJ.** Familial benign hypocalciuric hypercalcemia—from the clinic to the calcium sensor. *West J Med* 160: 579–580, 1994.
151. **Takaichi K, Kurokawa K.** High  $\text{Ca}^{2+}$  inhibits peptide hormone-dependent cAMP production specifically in thick ascending limbs of Henle. *Miner Electr Metab* 12: 342–346, 1986.
152. **Tfelt-Hansen J, Brown EM.** The calcium-sensing receptor in normal physiology and pathophysiology: a review. *Crit Rev Clin Lab Sci* 42: 35–70, 2005.
153. **Thogersson U, Costa J, Marx SJ.** The parathyroid glands in familial hypocalciuric hypercalcemia. *Hum Pathol* 12: 229–237, 1981.
154. **Timmers HJ, Karperien M, Hamdy NA, de Boer H, Hermus AR.** Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. *J Intern Med* 260: 177–182, 2006.
155. **Topala CN, Schoeber JP, Searchfield LE, Riccardi D, Hoenderop JG, Bindels RJ.** Activation of the  $\text{Ca}^{2+}$ -sensing receptor stimulates the activity of the epithelial  $\text{Ca}^{2+}$  channel TRPV5. *Cell Calcium* 45: 331–339, 2009.
156. **Valenti G, Procino G, Tamma G, Carosino M, Svelto M.** Minireview: aquaporin 2 trafficking. *Endocrinology* 146: 5063–5070, 2005.
157. **van Abel M, Hoenderop JG, van der Kemp AW, van Leeuwen JP, Bindels RJ.** Regulation of the epithelial  $\text{Ca}^{2+}$  channels in small intestine as studied by quantitative mRNA detection. *Am J Physiol Gastrointest Liver Physiol* 285: G78–G85, 2003.
158. **VanHouten J, Dann P, McGeoch G, Brown EM, Krapcho K, Neville M, Wysolmerski JJ.** The calcium-sensing receptor regulates mammary gland parathyroid hormone-related protein production and calcium transport. *J Clin Invest* 113: 598–608, 2004.
159. **Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaitre X, Paillard M, Planelles G, Dechaux M, Miller RT, Antignac C.** Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. *J Am Soc Nephrol* 13: 2259–2266, 2002.
160. **Vezzoli G, Tanini A, Ferrucci L, Soldati L, Bianchin C, Franceschelli F, Malentacchi C, Porfirio B, Adamo D, Terranegra A, Falchetti A, Cusi D, Bianchi G, Brandi ML.** Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. *J Am Soc Nephrol* 13: 2517–2523, 2002.
161. **Vezzoli G, Terranegra A, Arcidiacono T, Biasion R, Coviello D, Syren ML, Paloschi V, Giannini S, Mignogna G, Rubinacci A, Ferraretto A, Cusi D, Bianchi G, Soldati L.** R990G polymorphism of calcium-sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria. *Kidney Int* 71: 1155–1162, 2007.
162. **Waller S, Kurzawinski T, Spitz L, Thakker R, Cranston T, Pearce S, Cheetham T, van'T Hoff WG.** Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. *Eur J Pediatr* 163: 589–594, 2004.
163. **Wang W, Lu M, Balazy M, Hebert SC.** Phospholipase  $\text{A}_2$  is involved in mediating the effect of extracellular  $\text{Ca}^{2+}$  on apical  $\text{K}^+$  channels in rat TAL. *Am J Physiol Renal Physiol* 273: F421–F429, 1997.
164. **Wang WH, Lu M, Hebert SC.** Cytochrome  $\text{P-450}$  metabolites mediate extracellular  $\text{Ca}^{2+}$ -induced inhibition of apical  $\text{K}^+$  channels in the TAL. *Am J Physiol Cell Physiol* 271: C103–C111, 1996.
165. **Ward DT, Riccardi D.** Renal physiology of the extracellular calcium-sensing receptor. *Pflügers Arch* 445: 169–176, 2002.
166. **Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, Fujita T.** Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. *Lancet* 360: 692–694, 2002.
167. **Williams RR, Hunt SC, Hasstedt SJ, Hopkins PN, Wu LL, Berry TD, Stults BM, Barlow GK, Schumacher MC, Lifton RP, Lalouel JM.** Are there interactions and relations between genetic and environmental factors predisposing to high blood pressure? *Hypertension* 18: I29–I37, 1991.
168. **Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr.** Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1–34) versus calcitriol and calcium. *J Clin Endocrinol Metab* 88: 4214–4220, 2003.
169. **Yamamoto M, Akatsu T, Nagase T, Ogata E.** Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: is it possible to differentiate the two disorders? *J Clin Endocrinol Metab* 85: 4583–4591, 2000.
170. **Yano S, Sugimoto T, Kanzawa M, Tsukamoto T, Hattori T, Hattori S, Chihara K.** Association of polymorphic alleles of the calcium-sensing receptor gene with parathyroid hormone secretion in hemodialysis patients. *Nephron* 85: 317–323, 2000.
171. **Yarden N, Lavelin I, Genina O, Hurwitz S, Diaz R, Brown EM, Pines M.** Expression of calcium-sensing receptor gene by avian parathyroid gland in vivo: relationship to plasma calcium. *Gen Comp Endocrinol* 117: 173–181, 2000.
172. **Yokoyama K, Shigematsu T, Tsukada T, Hara S, Yamada A, Kawaguchi Y, Hosoya T.** Calcium-sensing receptor gene polymorphism affects the parathyroid response to moderate hypercalcemic suppression in patients with end-stage renal disease. *Clin Nephrol* 57: 131–135, 2002.